Vincenzo Di Marzo

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3108948/publications.pdf

Version: 2024-02-01

775	80,228	279	871
papers	citations	140 h-index	243 g-index

793	793	793	33365
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Expanding Research on Cannabis-Based Medicines for Liver Steatosis: A Low-Risk High-Reward Way Out of the Present Deadlock?. Cannabis and Cannabinoid Research, 2023, 8, 5-11.	1.5	2
2	Exploring the endocannabinoidome in genetically obese (ob/ob) and diabetic (db/db) mice: Links with inflammation and gut microbiota. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2022, 1867, 159056.	1.2	12
3	Nâ€Acylethanolamine acid amidase (NAAA) is dysregulated in colorectal cancer patients and its inhibition reduces experimental cancer growth. British Journal of Pharmacology, 2022, 179, 1679-1694.	2.7	6
4	Alterations of the endocannabinoid system and circulating and peripheral tissue levels of endocannabinoids in sarcopenic rats. Journal of Cachexia, Sarcopenia and Muscle, 2022, 13, 662-676.	2.9	9
5	Human and Mouse Eosinophils Differ in Their Ability to Biosynthesize Eicosanoids, Docosanoids, the Endocannabinoid 2-Arachidonoyl-glycerol and Its Congeners. Cells, 2022, 11, 141.	1.8	3
6	(Wh)olistic (E)ndocannabinoidome-Microbiome-Axis Modulation through (N)utrition (WHEN) to Curb Obesity and Related Disorders. Lipids in Health and Disease, 2022, 21, 9.	1.2	17
7	Early Blockade of CB1 Receptors Ameliorates Schizophrenia-like Alterations in the Neurodevelopmental MAM Model of Schizophrenia. Biomolecules, 2022, 12, 108.	1.8	9
8	Mutual Links between the Endocannabinoidome and the Gut Microbiome, with Special Reference to Companion Animals: A Nutritional Viewpoint. Animals, 2022, 12, 348.	1.0	8
9	Adipocyte-specific Nos2 deletion improves insulin resistance and dyslipidemia through brown fat activation in diet-induced obese mice. Molecular Metabolism, 2022, 57, 101437.	3.0	8
10	Three of a Kind: Control of the Expression of Liver-Expressed Antimicrobial Peptide 2 (LEAP2) by the Endocannabinoidome and the Gut Microbiome. Molecules, 2022, 27, 1.	1.7	38
11	Expression and Functions of the CB2 Receptor in Human Leukocytes. Frontiers in Pharmacology, 2022, 13, 826400.	1.6	22
12	Facile and Sustainable Synthesis of Commendamide and its Analogues. Frontiers in Chemistry, 2022, 10, 858854.	1.8	0
13	Amygdalar CB2 cannabinoid receptor mediates fear extinction deficits promoted by orexin-A/hypocretin-1. Biomedicine and Pharmacotherapy, 2022, 149, 112925.	2.5	11
14	Influence of diet on acute endocannabinoidome mediator levels post exercise in active women, a crossover randomized study. Scientific Reports, 2022, 12, .	1.6	10
15	Obesity: The Fat Tissue Disease Version of Cancer. Cells, 2022, 11, 1872.	1.8	13
16	Genetic Manipulation of sn-1-Diacylglycerol Lipase and CB₁ Cannabinoid Receptor Gain-of-Function Uncover Neuronal 2-Linoleoyl Glycerol Signaling in Drosophila melanogaster. Cannabis and Cannabinoid Research, 2021, 6, 119-136.	1.5	11
17	Intuitive eating is associated with elevated levels of circulating omega-3-polyunsaturated fatty acid-derived endocannabinoidome mediators. Appetite, 2021, 156, 104973.	1.8	4
18	Crosstalk between the transcriptional regulation of dopamine D2 and cannabinoid CB1 receptors in schizophrenia: Analyses in patients and in perinatal Î”9-tetrahydrocannabinol-exposed rats. Pharmacological Research, 2021, 164, 105357.	3.1	43

#	Article	IF	Citations
19	Beneficial Effects of Akkermansia muciniphila Are Not Associated with Major Changes in the Circulating Endocannabinoidome but Linked to Higher Mono-Palmitoyl-Glycerol Levels as New PPARÎ± Agonists. Cells, 2021, 10, 185.	1.8	43
20	Linking the Endocannabinoidome with Specific Metabolic Parameters in an Overweight and Insulin-Resistant Population: From Multivariate Exploratory Analysis to Univariate Analysis and Construction of Predictive Models. Cells, 2021, 10, 71.	1.8	6
21	A Glucuronic Acid-Palmitoylethanolamide Conjugate (GLUPEA) Is an Innovative Drug Delivery System and a Potential Bioregulator. Cells, 2021, 10, 450.	1.8	2
22	Orexin-A/Hypocretin-1 Controls the VTA-NAc Mesolimbic Pathway via Endocannabinoid-Mediated Disinhibition of Dopaminergic Neurons in Obese Mice. Frontiers in Synaptic Neuroscience, 2021, 13, 622405.	1.3	11
23	The gut microbiome, endocannabinoids and metabolic disorders. Journal of Endocrinology, 2021, 248, R83-R97.	1.2	46
24	2-Pentadecyl-2-oxazoline ameliorates memory impairment and depression-like behaviour in neuropathic mice: possible role of adrenergic alpha2- and H3 histamine autoreceptors. Molecular Brain, 2021, 14, 28.	1.3	13
25	Editorial on â€œCannabis and cannabinoids: history, practice and socio-economical inferences of a controversial plantâ€• Rendiconti Lincei, 2021, 32, 1-4.	1.0	0
26	N-palmitoyl-D-glucosamine, A Natural Monosaccharide-Based Glycolipid, Inhibits TLR4 and Prevents LPS-Induced Inflammation and Neuropathic Pain in Mice. International Journal of Molecular Sciences, 2021, 22, 1491.	1.8	19
27	Deletion of the gene encoding prostamide/prostaglandin F synthase reveals an important role in regulating intraocular pressure. Prostaglandins Leukotrienes and Essential Fatty Acids, 2021, 165, 102235.	1.0	2
28	N-Oleoylglycine and N-Oleoylalanine Do Not Modify Tolerance to Nociception, Hyperthermia, and Suppression of Activity Produced by Morphine. Frontiers in Synaptic Neuroscience, 2021, 13, 620145.	1.3	5
29	Synthesis and molecular targets of N-13-hydroxy-octadienoyl-ethanolamine, a novel endogenous bioactive 15-lipoxygenase-derived metabolite of N-linoleoyl-ethanolamine found in the skin and saliva. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2021, 1866, 158954.	1.2	4
30	Identification and Characterization of Cannabidiol as an OX1R Antagonist by Computational and In Vitro Functional Validation. Biomolecules, 2021, 11, 1134.	1.8	8
31	Oral Capsaicinoid Administration Alters the Plasma Endocannabinoidome and Fecal Microbiota of Reproductive-Aged Women Living with Overweight and Obesity. Biomedicines, 2021, 9, 1246.	1.4	7
32	Spontaneous and Naloxone-Precipitated Withdrawal Behaviors From Chronic Opiates are Accompanied by Changes in N-Oleoylglycine and N-Oleoylalanine Levels in the Brain and Ameliorated by Treatment With These Mediators. Frontiers in Pharmacology, 2021, 12, 706703.	1.6	9
33	Biosynthesis of the Novel Endogenous 15-Lipoxygenase Metabolites N-13-Hydroxy-octodecadienoyl-ethanolamine and 13-Hydroxy-octodecadienoyl-glycerol by Human Neutrophils and Eosinophils. Cells, 2021, 10, 2322.	1.8	11
34	Maternal omega-3 intake differentially affects the endocannabinoid system in the progeny`s neocortex and hippocampus: Impact on synaptic markers. Journal of Nutritional Biochemistry, 2021, 96, 108782.	1.9	5
35	Cannabinoids: a class of unique natural products with unique pharmacology. Rendiconti Lincei, 2021, 32, 5-15.	1.0	14
36	Efficacy of combined therapy with fish oil and phytocannabinoids in murine intestinal inflammation. Phytotherapy Research, 2021, 35, 517-529.	2.8	21

#	Article	IF	Citations
37	Orexin-A and endocannabinoids are involved in obesity-associated alteration of hippocampal neurogenesis, plasticity, and episodic memory in mice. Nature Communications, 2021, 12, 6137.	5.8	22
38	Kahweol, a natural diterpene from coffee, induces peripheral antinociception by endocannabinoid system activation. Brazilian Journal of Medical and Biological Research, 2021, 54, e11071.	0.7	1
39	Effect of Docosahexaenoic Acid (DHA) at the Enteric Level in a Synucleinopathy Mouse Model. Nutrients, 2021, 13, 4218.	1.7	4
40	Assessment of the Effects of Dietary Vitamin D Levels on Olanzapine-Induced Metabolic Side Effects: Focus on the Endocannabinoidome-Gut Microbiome Axis. International Journal of Molecular Sciences, 2021, 22, 12361.	1.8	4
41	Endocannabinoids. , 2021, , 597-605.		0
42	Biological basis of cannabinoid medicines. Science, 2021, 374, 1449-1450.	6.0	10
43	Altered gut microbiota and endocannabinoid system tone in vitamin D deficiency-mediated chronic pain. Brain, Behavior, and Immunity, 2020, 85, 128-141.	2.0	76
44	Life-long epigenetic programming of cortical architecture by maternal â€˜Westernâ€™ diet during pregnancy. Molecular Psychiatry, 2020, 25, 22-36.	4.1	28
45	Germ-free mice exhibit profound gut microbiota-dependent alterations of intestinal endocannabinoidome signaling. Journal of Lipid Research, 2020, 61, 70-85.	2.0	80
46	Acute naloxone-precipitated morphine withdrawal elicits nausea-like somatic behaviors in rats in a manner suppressed by N-oleoylglycine. Psychopharmacology, 2020, 237, 375-384.	1.5	12
47	Cannabinoids and the expanded endocannabinoid system in neurological disorders. Nature Reviews Neurology, 2020, 16, 9-29.	4.9	564
48	Alterations of brain endocannabinoidome signaling in germ-free mice. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2020, 1865, 158786.	1.2	23
49	Su1124 SMALL INTESTINE EPITHELIAL ORGANOIDS AS A MODEL TO INVESTIGATE THE ROLE OF THE ENDOCANNABINOIDOME ON INTESTINAL PARACELLULAR PERMEABILITY DURING INFLAMMATION. Gastroenterology, 2020, 158, S-516.	0.6	1
50	Manipulation of Dietary Amino Acids Prevents and Reverses Obesity in Mice Through Multiple Mechanisms That Modulate Energy Homeostasis. Diabetes, 2020, 69, 2324-2339.	0.3	25
51	Design, Synthesis and In Vitro Experimental Validation of Novel TRPV4 Antagonists Inspired by Labdane Diterpenes. Marine Drugs, 2020, 18, 519.	2.2	11
52	Dietary fatty acid intake and gut microbiota determine circulating endocannabinoidome signaling beyond the effect of body fat. Scientific Reports, 2020, 10, 15975.	1.6	50
53	Mgll Knockout Mouse Resistance to Diet-Induced Dysmetabolism Is Associated with Altered Gut Microbiota. Cells, 2020, 9, 2705.	1.8	24
54	Fish Oil, Cannabidiol and the Gut Microbiota: An Investigation in a Murine Model of Colitis. Frontiers in Pharmacology, 2020, 11, 585096.	1.6	36

#	Article	IF	Citations
55	Hepatic NAPE-PLD Is a Key Regulator of Liver Lipid Metabolism. Cells, 2020, 9, 1247.	1.8	17
56	Tu1205 OBESITY-RELATED ENDOGENOUS MICROENVIRONMENT IMPACTS INSULIN SIGNALING AND INTESTINAL FUNCTIONS OF INTESTINAL ORGANOIDS. Gastroenterology, 2020, 158, S-1018.	0.6	0
57	Oleoyl alanine (HU595): a stable monomethylated oleoyl glycine interferes with acute naloxone precipitated morphine withdrawal in male rats. Psychopharmacology, 2020, 237, 2753-2765.	1.5	11
58	Design, Synthesis, and Physicochemical and Pharmacological Profiling of 7-Hydroxy-5-oxopyrazolo[4,3-‹i›b‹/i›]pyridine-6-carboxamide Derivatives with Antiosteoarthritic Activity In Vivo. Journal of Medicinal Chemistry, 2020, 63, 7369-7391.	2.9	18
59	Treatment With 2-Pentadecyl-2-Oxazoline Restores Mild Traumatic Brain Injury-Induced Sensorial and Neuropsychiatric Dysfunctions. Frontiers in Pharmacology, 2020, 11, 91.	1.6	15
60	Cannabidiol in sport: Ergogenic or else?. Pharmacological Research, 2020, 156, 104764.	3.1	14
61	Obesity Affects the Microbiotaâ€“Gutâ€“Brain Axis and the Regulation Thereof by Endocannabinoids and Related Mediators. International Journal of Molecular Sciences, 2020, 21, 1554.	1.8	60
62	Role of 2-Arachidonoyl-Glycerol and CB1 Receptors in Orexin-A-Mediated Prevention of Oxygenâ€“Glucose Deprivation-Induced Neuronal Injury. Cells, 2020, 9, 1507.	1.8	12
63	Endocannabinoid hydrolysis inhibition unmasks that unsaturated fatty acids induce a robust biosynthesis of 2â€arachidonoylâ€glycerol and its congeners in human myeloid leukocytes. FASEB Journal, 2020, 34, 4253-4265.	0.2	26
64	Phytocannabinoids promote viability and functional adipogenesis of bone marrow-derived mesenchymal stem cells through different molecular targets. Biochemical Pharmacology, 2020, 175, 113859.	2.0	17
65	Desensitization of transient receptor potential vanilloid type-1 (TRPV1) channel as promising therapy of irritable bowel syndrome: characterization of the action of palvanil in the mouse gastrointestinal tract. Naunyn-Schmiedeberg's Archives of Pharmacology, 2020, 393, 1357-1364.	1.4	12
66	Anticonvulsive Properties of Cannabidiol in a Model of Generalized Seizure Are Transient Receptor Potential Vanilloid 1 Dependent. Cannabis and Cannabinoid Research, 2020, 5, 145-149.	1.5	36
67	Protective Effects of ‹i›N‹/i›-Oleoylglycine in a Mouse Model of Mild Traumatic Brain Injury. ACS Chemical Neuroscience, 2020, 11, 1117-1128.	1.7	15
68	Î±2-Adrenoceptor agonist induces peripheral antinociception via the endocannabinoid system. Pharmacological Reports, 2020, 72, 96-103.	1.5	2
69	Effects of BPA on zebrafish gonads: Focus on the endocannabinoid system. Environmental Pollution, 2020, 264, 114710.	3.7	26
70	Synthetic bioactive olivetol-related amides: The influence of the phenolic group in cannabinoid receptor activity. Bioorganic and Medicinal Chemistry, 2020, 28, 115513.	1.4	3
71	Altered dopamine D3 receptor gene expression in MAM model of schizophrenia is reversed by peripubertal cannabidiol treatment. Biochemical Pharmacology, 2020, 177, 114004.	2.0	36
72	Adverse effects of Î”9-tetrahydrocannabinol on neuronal bioenergetics during postnatal development. JCI Insight, 2020, 5, .	2.3	12

#	Article	IF	Citations
73	The endocannabinoidome as a substrate for noneuphoric phytocannabinoid action and gut microbiome dysfunction in neuropsychiatric disorders. Dialogues in Clinical Neuroscience, 2020, 22, 259-269.	1.8	42
74	Endocannabinoids. , 2020, , 1-9.		0
75	Effects of nonâ€euphoric plant cannabinoids on muscle quality and performance of dystrophic mdx mice. British Journal of Pharmacology, 2019, 176, 1568-1584.	2.7	51
76	Lifestyle and Metabolic Syndrome: Contribution of the Endocannabinoidome. Nutrients, 2019, 11, 1956.	1.7	89
77	Targeted Lipidomics Investigation of Nâ€acylethanolamines in a Transgenic Mouse Model of AD: A Longitudinal Study. European Journal of Lipid Science and Technology, 2019, 121, 1900015.	1.0	3
78	Cannabidiol improves vocal learning-dependent recovery from, and reduces magnitude of deficits following, damage to a cortical-like brain region in a songbird pre-clinical animal model. Neuropharmacology, 2019, 158, 107716.	2.0	9
79	Structure-activity relationships of thiazole and benzothiazole derivatives as selective cannabinoid CB2 agonists with inÂvivo anti-inflammatory properties. European Journal of Medicinal Chemistry, 2019, 180, 154-170.	2.6	47
80	Altered Metabolism of Phospholipases, Diacylglycerols, Endocannabinoids, and N-Acylethanolamines in Patients with Mastocytosis. Journal of Immunology Research, 2019, 2019, 1-14.	0.9	8
81	The Expanded Endocannabinoid System/Endocannabinoidome as a Potential Target for Treating Diabetes Mellitus. Current Diabetes Reports, 2019, 19, 117.	1.7	56
82	Human leukocytes differentially express endocannabinoid-glycerol lipases and hydrolyze 2-arachidonoyl-glycerol and its metabolites from the 15-lipoxygenase and cyclooxygenase pathways. Journal of Leukocyte Biology, 2019, 106, 1337-1347.	1.5	17
83	Effects of diisononyl phthalate (DiNP) on the endocannabinoid and reproductive systems of male gilthead sea bream (Sparus aurata) during the spawning season. Archives of Toxicology, 2019, 93, 727-741.	1.9	20
84	Effects of Dietary Bisphenol A on the Reproductive Function of Gilthead Sea Bream (Sparus aurata) Testes. International Journal of Molecular Sciences, 2019, 20, 5003.	1.8	15
85	The non-euphoric phytocannabinoid cannabidivarin counteracts intestinal inflammation in mice and cytokine expression in biopsies from UC pediatric patients. Pharmacological Research, 2019, 149, 104464.	3.1	55
86	Intestinal epithelial N-acylphosphatidylethanolamine phospholipase D links dietary fat to metabolic adaptations in obesity and steatosis. Nature Communications, 2019, 10, 457.	5.8	100
87	Discovery of novel benzofuran-based compounds with neuroprotective and immunomodulatory properties for Alzheimer's disease treatment. European Journal of Medicinal Chemistry, 2019, 178, 243-258.	2.6	32
88	Summary of the International Conference on Onco-Nephrology: an emerging field in medicine. Kidney International, 2019, 96, 555-567.	2.6	47
89	Cannabidivarin completely rescues cognitive deficits and delays neurological and motor defects in male Mecp2 mutant mice. Journal of Psychopharmacology, 2019, 33, 894-907.	2.0	38
90	Oleoyl glycine: interference with the aversive effects of acute naloxone-precipitated MWD, but not morphine reward, in male Sprague–Dawley rats. Psychopharmacology, 2019, 236, 2623-2633.	1.5	12

#	Article	IF	Citations
91	Orexin-A Prevents Lipopolysaccharide-Induced Neuroinflammation at the Level of the Intestinal Barrier. Frontiers in Endocrinology, 2019, 10, 219.	1.5	24
92	In Silico Identification and Experimental Validation of (â˜')-Muqubilin A, a Marine Norterpene Peroxide, as PPARÎ±/Î³-RXRÎ± Agonist and RARÎ± Positive Allosteric Modulator. Marine Drugs, 2019, 17, 110.	2.2	11
93	Palmitoylethanolamide counteracts substance P-induced mast cell activation in vitro by stimulating diacylglycerol lipase activity. Journal of Neuroinflammation, 2019, 16, 274.	3.1	39
94	Rapid and Concomitant Gut Microbiota and Endocannabinoidome Response to Diet-Induced Obesity in Mice. MSystems, 2019, 4, .	1.7	52
95	FAAH-Catalyzed Câ€“C Bond Cleavage of a New Multitarget Analgesic Drug. ACS Chemical Neuroscience, 2019, 10, 424-437.	1.7	2
96	Peripubertal cannabidiol treatment rescues behavioral and neurochemical abnormalities in the MAM model of schizophrenia. Neuropharmacology, 2019, 146, 212-221.	2.0	59
97	Systemic administration of serotonin exacerbates abdominal pain and colitis via interaction with the endocannabinoid system. Biochemical Pharmacology, 2019, 161, 37-51.	2.0	22
98	Identification and characterization of phytocannabinoids as novel dual PPARÎ±/Î³ agonists by a computational and in vitro experimental approach. Biochimica Et Biophysica Acta - General Subjects, 2019, 1863, 586-597.	1.1	55
99	Synthesis of novel 2-(1-adamantanylcarboxamido)thiophene derivatives. Selective cannabinoid type 2 (CB2) receptor agonists as potential agents for the treatment of skin inflammatory disease. European Journal of Medicinal Chemistry, 2019, 161, 239-251.	2.6	25
100	Ultra-micronized palmitoylethanolamide rescues the cognitive decline-associated loss of neural plasticity in the neuropathic mouse entorhinal cortex-dentate gyrus pathway. Neurobiology of Disease, 2019, 121, 106-119.	2.1	41
101	N-Oleoyl-glycine reduces nicotine reward and withdrawal in mice. Neuropharmacology, 2019, 148, 320-331.	2.0	37
102	Cannabinoid receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database. IUPHAR/BPS Guide To Pharmacology CITE, 2019, 2019, .	0.2	8
103	Role of Bisphenol A on the Endocannabinoid System at central and peripheral levels: Effects on adult female zebrafish. Chemosphere, 2018, 205, 118-125.	4.2	19
104	Anti-inflammatory Properties of Cannabidiol, a Nonpsychotropic Cannabinoid, in Experimental Allergic Contact Dermatitis. Journal of Pharmacology and Experimental Therapeutics, 2018, 365, 652-663.	1.3	114
105	Effects of repeated longâ€term psychosocial stress and acute cannabinoid exposure on mouse corticostriatal circuitries: Implications for neuropsychiatric disorders. CNS Neuroscience and Therapeutics, 2018, 24, 528-538.	1.9	11
106	Endocannabinoid Tone Regulates Human Sebocyte Biology. Journal of Investigative Dermatology, 2018, 138, 1699-1706.	0.3	17
107	Antibiotic-induced microbiota perturbation causes gut endocannabinoidome changes, hippocampal neuroglial reorganization and depression in mice. Brain, Behavior, and Immunity, 2018, 67, 230-245.	2.0	246
108	The Involvement of the Endocannabinoid System in the Peripheral Antinociceptive Action of Ketamine. Journal of Pain, 2018, 19, 487-495.	0.7	19

#	Article	IF	Citations
109	Fishing for Targets of Alien Metabolites: A Novel Peroxisome Proliferator-Activated Receptor (PPAR) Agonist from a Marine Pest. Marine Drugs, 2018, 16, 431.	2.2	27
110	Genetic and pharmacological regulation of the endocannabinoid CB1 receptor in Duchenne muscular dystrophy. Nature Communications, 2018, 9, 3950.	5.8	43
111	Reversal of albuminuria by combined AM6545 and perindopril therapy in experimental diabetic nephropathy. British Journal of Pharmacology, 2018, 175, 4371-4385.	2.7	22
112	Elongation of the Hydrophobic Chain as a Molecular Switch: Discovery of Capsaicin Derivatives and Endogenous Lipids as Potent Transient Receptor Potential Vanilloid Channel 2 Antagonists. Journal of Medicinal Chemistry, 2018, 61, 8255-8281.	2.9	11
113	Î”9-tetrahydrocannabivarin impairs epithelial calcium transport through inhibition of TRPV5 and TRPV6. Pharmacological Research, 2018, 136, 83-89.	3.1	20
114	Disruption of the gonadal endocannabinoid system in zebrafish exposed to diisononyl phthalate. Environmental Pollution, 2018, 241, 1-8.	3.7	31
115	Development of Potent Inhibitors of Fatty Acid Amide Hydrolase Useful for the Treatment of Neuropathic Pain. ChemMedChem, 2018, 13, 2090-2103.	1.6	19
116	Oral Ultramicronized Palmitoylethanolamide: Plasma and Tissue Levels and Spinal Anti-hyperalgesic Effect. Frontiers in Pharmacology, 2018, 9, 249.	1.6	58
117	CB1 receptor activation induces intracellular Ca2+ mobilization and 2-arachidonoylglycerol release in rodent spinal cord astrocytes. Scientific Reports, 2018, 8, 10562.	1.6	42
118	Overlapping Distribution of Orexin and Endocannabinoid Receptors and Their Functional Interaction in the Brain of Adult Zebrafish. Frontiers in Neuroanatomy, 2018, 12, 62.	0.9	23
119	New approaches and challenges to targeting the endocannabinoid system. Nature Reviews Drug Discovery, 2018, 17, 623-639.	21.5	346
120	Experimental ischemia/reperfusion model impairs endocannabinoid signaling and Na+/K+ ATPase expression and activity in kidney proximal tubule cells. Biochemical Pharmacology, 2018, 154, 482-491.	2.0	15
121	Endocrine disruptors in the diet of male Sparus aurata: Modulation of the endocannabinoid system at the hepatic and central level by Di-isononyl phthalate and Bisphenol A. Environment International, 2018, 119, 54-65.	4.8	38
122	Combined CoMFA and CoMSIA 3D-QSAR study of benzimidazole and benzothiophene derivatives with selective affinity for the CB2 cannabinoid receptor. European Journal of Pharmaceutical Sciences, 2017, 101, 1-10.	1.9	20
123	Allodynia Lowering Induced by Cannabinoids and Endocannabinoids (ALICE). Pharmacological Research, 2017, 119, 272-277.	3.1	22
124	Randomised clinical trial: the analgesic properties of dietary supplementation with palmitoylethanolamide and polydatin in irritable bowel syndrome. Alimentary Pharmacology and Therapeutics, 2017, 45, 909-922.	1.9	81
125	Pharmacological inhibition of MAGL attenuates experimental colon carcinogenesis. Pharmacological Research, 2017, 119, 227-236.	3.1	53
126	Participants with Normal Weight or with Obesity Show Different Relationships of 6-n-Propylthiouracil (PROP) Taster Status with BMI and Plasma Endocannabinoids. Scientific Reports, 2017, 7, 1361.	1.6	29

#	Article	IF	Citations
127	Role of the endocannabinoid system in the control of mouse myometrium contractility during the menstrual cycle. Biochemical Pharmacology, 2017, 124, 83-93.	2.0	10
128	Endocannabinoid-dependent disinhibition of orexinergic neurons: Electrophysiological evidence in leptin-knockout obese mice. Molecular Metabolism, 2017, 6, 594-601.	3.0	8
129	A <scp>TRPV</scp> 1â€toâ€secretagogin regulatory axis controls pancreatic Î²â€cell survival by modulating protein turnover. EMBO Journal, 2017, 36, 2107-2125.	3.5	52
130	Activity-based protein profiling reveals off-target proteins of the FAAH inhibitor BIA 10-2474. Science, 2017, 356, 1084-1087.	6.0	251
131	Dual therapy targeting the endocannabinoid system prevents experimental diabetic nephropathy. Nephrology Dialysis Transplantation, 2017, 32, 1655-1665.	0.4	42
132	Development of a Rapid LC-MS/MS Method for the Quantification of Cannabidiol, Cannabidivarin, Î”⁹-Tetrahydrocannabivarin, and Cannabigerol in Mouse Peripheral Tissues. Analytical Chemistry, 2017, 89, 4749-4755.	3.2	10
133	Palmitoylethanolamide induces microglia changes associated with increased migration and phagocytic activity: involvement of the CB2 receptor. Scientific Reports, 2017, 7, 375.	1.6	103
134	Cannabinoid CB2 receptor ligand profiling reveals biased signalling and off-target activity. Nature Communications, 2017, 8, 13958.	5.8	265
135	Plasma palmitoylethanolamide (PEA) as a potential biomarker for impaired coronary function. International Journal of Cardiology, 2017, 231, 1-5.	0.8	11
136	Dose-Specific Effects of Di-Isononyl Phthalate on the Endocannabinoid System and on Liver of Female Zebrafish. Endocrinology, 2017, 158, 3462-3476.	1.4	45
137	Effects of curcumin and curcumin analogues on TRP channels. FÃ¬toterapÃ¬Ã¢, 2017, 122, 126-131.	1.1	31
138	Targeting fatty acid amide hydrolase and transient receptor potential vanilloidâ€1 simultaneously to modulate colonic motility and visceral sensation in the mouse: A pharmacological intervention with Nâ€arachidonoylâ€serotonin (<scp>AA</scp>â€5â€<scp>HT</scp>). Neurogastroenterology and Motility, 2017, 29, e13148.	1.6	10
139	Techniques for the Cellular and Subcellular Localization of Endocannabinoid Receptors and Enzymes in the Mammalian Brain. Methods in Enzymology, 2017, 593, 61-98.	0.4	7
140	The time course of erythrocyte membrane fatty acid concentrations during and after treatment of non-human primates with increasing doses of an omega-3 rich phospholipid preparation derived from krill-oil. Lipids in Health and Disease, 2017, 16, 16.	1.2	11
141	Hedonic eating in Praderâ€“Willi syndrome is associated with blunted PYY secretion. Food and Nutrition Research, 2017, 61, 1297553.	1.2	11
142	CB 1 Cannabinoid Receptors Mediate Cognitive Deficits and Structural Plasticity Changes During Nicotine Withdrawal. Biological Psychiatry, 2017, 81, 625-634.	0.7	24
143	The pharmacology of palmitoylethanolamide and first data on the therapeutic efficacy of some of its new formulations. British Journal of Pharmacology, 2017, 174, 1349-1365.	2.7	227
144	Chronic exposure to cannabinoids during adolescence causes longâ€lasting behavioral deficits in adult mice. Addiction Biology, 2017, 22, 1778-1789.	1.4	48

#	Article	IF	Citations
145	2-Pentadecyl-2-Oxazoline, the Oxazoline of Pea, Modulates Carrageenan-Induced Acute Inflammation. Frontiers in Pharmacology, 2017, 8, 308.	1.6	49
146	Palmitoylethanolamide Supplementation during Sensitization Prevents Airway Allergic Symptoms in the Mouse. Frontiers in Pharmacology, 2017, 8, 857.	1.6	35
147	Polymorphism rs1761667 in the CD36 Gene Is Associated to Changes in Fatty Acid Metabolism and Circulating Endocannabinoid Levels Distinctively in Normal Weight and Obese Subjects. Frontiers in Physiology, 2017, 8, 1006.	1.3	34
148	Role of N-Arachidonoyl-Serotonin (AA-5-HT) in Sleep-Wake Cycle Architecture, Sleep Homeostasis, and Neurotransmitters Regulation. Frontiers in Molecular Neuroscience, 2017, 10, 152.	1.4	26
149	Characterization of endocannabinoids and related acylethanolamides in the synovial fluid of dogs with osteoarthritis: a pilot study. BMC Veterinary Research, 2017, 13, 309.	0.7	24
150	Peripheral Endocannabinoid Responses to Hedonic Eating in Binge-Eating Disorder. Nutrients, 2017, 9, 1377.	1.7	21
151	The Endocannabinoid System in Leptin-Driven Changes of Orexinergic Signaling Under Physiological and Pathological Conditions. , 2017, , 1-26.		3
152	Treatment with the GPR55 antagonist CID16020046 increases neutrophil activation in mouse atherogenesis. Thrombosis and Haemostasis, 2016, 116, 987-997.	1.8	28
153	An Orally Active Cannabis Extract with High Content in Cannabidiol attenuates Chemically-induced Intestinal Inflammation and Hypermotility in the Mouse. Frontiers in Pharmacology, 2016, 7, 341.	1.6	89
154	Discovery of novel Tetrahydrobenzo[b]thiophene and pyrrole based scaffolds as potent and selective CB2 receptor ligands: The structural elements controlling binding affinity, selectivity and functionality. European Journal of Medicinal Chemistry, 2016, 122, 619-634.	2.6	28
155	Exercise training and high-fat diet elicit endocannabinoid system modifications in the rat hypothalamus and hippocampus. Journal of Physiology and Biochemistry, 2016, 73, 335-347.	1.3	16
156	Sex-dependent effects of neonatal maternal deprivation on endocannabinoid levels in the adipose tissue: influence of diet. Journal of Physiology and Biochemistry, 2016, 73, 349-357.	1.3	4
157	Early Low-Fat Diet Enriched With Linolenic Acid Reduces Liver Endocannabinoid Tone and Improves Late Glycemic Control After a High-Fat Diet Challenge in Mice. Diabetes, 2016, 65, 1824-1837.	0.3	20
158	Bisphenol A Induces Fatty Liver by an Endocannabinoid-Mediated Positive Feedback Loop. Endocrinology, 2016, 157, 1751-1763.	1.4	67
159	Orexin-A represses satiety-inducing POMC neurons and contributes to obesity via stimulation of endocannabinoid signaling. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 4759-4764.	3.3	68
160	Palmitoylethanolamide reduces inflammation and itch in a mouse model of contact allergic dermatitis. European Journal of Pharmacology, 2016, 791, 669-674.	1.7	42
161	From Phytocannabinoids to Cannabinoid Receptors and Endocannabinoids: Pleiotropic Physiological and Pathological Roles Through Complex Pharmacology. Physiological Reviews, 2016, 96, 1593-1659.	13.1	317
162	Synthesis, binding assays, cytotoxic activity and docking studies of benzimidazole and benzothiophene derivatives with selective affinity for the CB2 cannabinoid receptor. European Journal of Medicinal Chemistry, 2016, 124, 17-35.	2.6	25

#	Article	IF	Citations
163	Pure Î” 9 -tetrahydrocannabivarin and a Cannabis sativa extract with high content in Î” 9 -tetrahydrocannabivarin inhibit nitrite production in murine peritoneal macrophages. Pharmacological Research, 2016, 113, 199-208.	3.1	32
164	Analysis of endocannabinoid signaling elements and related proteins in lymphocytes of patients with Dravet syndrome. Pharmacology Research and Perspectives, 2016, 4, e00220.	1.1	13
165	Formation of OX-1R/CB 1 R heteromeric complexes in embryonic mouse hypothalamic cells: Effect on intracellular calcium, 2-arachidonoyl-glycerol biosynthesis and ERK phosphorylation. Pharmacological Research, 2016, 111, 600-609.	3.1	22
166	Important role of endocannabinoid signaling in the development of functional vision and locomotion in zebrafish. FASEB Journal, 2016, 30, 4275-4288.	0.2	25
167	The multiplicity of spinal AA-5-HT anti-nociceptive action in a rat model of neuropathic pain. Pharmacological Research, 2016, 111, 251-263.	3.1	24
168	Fatty Acid Amide Hydrolase (FAAH), Acetylcholinesterase (AChE), and Butyrylcholinesterase (BuChE): Networked Targets for the Development of Carbamates as Potential Anti-Alzheimerâ€™s Disease Agents. Journal of Medicinal Chemistry, 2016, 59, 6387-6406.	2.9	66
169	The antiâ€inflammatory mediator palmitoylethanolamide enhances the levels of 2â€arachidonoylâ€glycerol and potentiates its actions at TRPV1 cation channels. British Journal of Pharmacology, 2016, 173, 1154-1162.	2.7	105
170	Therapy with a Selective Cannabinoid Receptor Type 2 Agonist Limits Albuminuria and Renal Injury in Mice with Type 2 Diabetic Nephropathy. Nephron, 2016, 132, 59-69.	0.9	36
171	Arylboronic acids as dual-action FAAH and TRPV1 ligands. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 1401-1405.	1.0	13
172	Responses of peripheral endocannabinoids and endocannabinoid-related compounds to hedonic eating in obesity. European Journal of Nutrition, 2016, 55, 1799-1805.	1.8	50
173	Investigations on the 4-Quinolone-3-carboxylic Acid Motif. 7. Synthesis and Pharmacological Evaluation of 4-Quinolone-3-carboxamides and 4-Hydroxy-2-quinolone-3-carboxamides as High Affinity Cannabinoid Receptor 2 (CB2R) Ligands with Improved Aqueous Solubility. Journal of Medicinal Chemistry, 2016, 59, 1052-1067.	2.9	32
174	Adelmidrol increases the endogenous concentrations of palmitoylethanolamide in canine keratinocytes and down-regulates an inflammatory reaction in an in vitro model of contact allergic dermatitis. Veterinary Journal, 2016, 207, 85-91.	0.6	24
175	Effects of chronic exercise on the endocannabinoid system in Wistar rats with high-fat diet-induced obesity. Journal of Physiology and Biochemistry, 2016, 72, 183-199.	1.3	20
176	Social defeat leads to changes in the endocannabinoid system: An overexpression of calreticulin and motor impairment in mice. Behavioural Brain Research, 2016, 303, 34-43.	1.2	15
177	Development and Pharmacological Characterization of Selective Blockers of 2-Arachidonoyl Glycerol Degradation with Efficacy in Rodent Models of Multiple Sclerosis and Pain. Journal of Medicinal Chemistry, 2016, 59, 2612-2632.	2.9	70
178	Elevated Systemic Levels of Endocannabinoids and Related Mediators Across the Menstrual Cycle in Women With Endometriosis. Reproductive Sciences, 2016, 23, 1071-1079.	1.1	39
179	Endocannabinoid regulation in white and brown adipose tissue following thermogenic activation. Journal of Lipid Research, 2016, 57, 464-473.	2.0	57
180	Design and Synthesis of New Transient Receptor Potential Vanilloid Type-1 (TRPV1) Channel Modulators: Identification, Molecular Modeling Analysis, and Pharmacological Characterization of the N-(4-Hydroxy-3-methoxybenzyl)-4-(thiophen-2-yl)butanamide, a Small Molecule Endowed with Agonist TRPV1 Activity and Protective Effects against Oxidative Stress. ACS Chemical Neuroscience, 2016, 7, 737-748.	1.7	20

#	Article	IF	Citations
181	Endovanilloid control of pain modulation by the rostroventromedial medulla in an animal model of diabetic neuropathy. Neuropharmacology, 2016, 107, 49-57.	2.0	24
182	Endocannabinoids and endocannabinoid-related mediators: Targets, metabolism and role in neurological disorders. Progress in Lipid Research, 2016, 62, 107-128.	5.3	276
183	TRPA1 channels as targets for resveratrol and related stilbenoids. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 899-902.	1.0	14
184	At the Tip of an Iceberg: Prenatal Marijuana and Its Possible Relation to Neuropsychiatric Outcome in the Offspring. Biological Psychiatry, 2016, 79, e33-e45.	0.7	73
185	Antitumor effect of pyrrolo-1,5-benzoxazepine-15 and its synergistic effect with Oxaliplatin and 5-FU in colorectal cancer cells. Cancer Biology and Therapy, 2016, 17, 849-858.	1.5	20
186	Human lung-resident macrophages express CB1 and CB2 receptors whose activation inhibits the release of angiogenic and lymphangiogenic factors. Journal of Leukocyte Biology, 2016, 99, 531-540.	1.5	98
187	Orexin-A and Endocannabinoid Activation of the Descending Antinociceptive Pathway Underlies Altered Pain Perception in Leptin Signaling Deficiency. Neuropsychopharmacology, 2016, 41, 508-520.	2.8	45
188	Anandamide interferes with human endometrial stromalâ€derived cell differentiation: An effect dependent on inhibition of cyclooxygenaseâ€2 expression and prostaglandin E₂ release. BioFactors, 2016, 42, 277-286.	2.6	15
189	Harnessing the pyrroloquinoxaline scaffold for FAAH and MAGL interaction: definition of the structural determinants for enzyme inhibition. RSC Advances, 2016, 6, 64651-64664.	1.7	19
190	Chalcone Derivatives Activate and Desensitize the Transient Receptor Potential Ankyrin 1 Cation Channel, Subfamily A, Member 1 TRPA1 Ion Channel: Structure-Activity Relationships in vitro and Anti-Nociceptive and Anti-inflammatory Activity in vivo. CNS and Neurological Disorders - Drug Targets, 2016, 15, 987-994.	0.8	14
191	Elevation of Plasma 2-Arachidonoylglycerol Levels in Alzheimerâ€™s Disease Patients as a Potential Protective Mechanism against Neurodegenerative Decline. Journal of Alzheimer's Disease, 2015, 46, 497-506.	1.2	46
192	Anticipatory and consummatory effects of (hedonic) chocolate intake are associated with increased circulating levels of the orexigenic peptide ghrelin and endocannabinoids in obese adults. Food and Nutrition Research, 2015, 59, 29678.	1.2	36
193	Genetic deletion of monoacylglycerol lipase leads to impaired cannabinoid receptor <scp>CB</scp>₁R signaling and anxietyâ€like behavior. Journal of Neurochemistry, 2015, 135, 799-813.	2.1	74
194	Anandamide drives cell cycle progression through CB1 receptors in a rat model of synchronized liver regeneration. Journal of Cellular Physiology, 2015, 230, 2905-2914.	2.0	11
195	Circulating Endocannabinoids and the Polymorphism 385C>A in Fatty Acid Amide Hydrolase (FAAH) Gene May Identify the Obesity Phenotype Related to Cardiometabolic Risk: A Study Conducted in a Brazilian Population of Complex Interethnic Admixture. PLoS ONE, 2015, 10, e0142728.	1.1	27
196	Exposure to Allergen Causes Changes in NTS Neural Activities after Intratracheal Capsaicin Application, in Endocannabinoid Levels and in the Glia Morphology of NTS. BioMed Research International, 2015, 2015, 1-10.	0.9	22
197	Inhibiting endocannabinoid biosynthesis: a novel approach to the treatment of constipation. British Journal of Pharmacology, 2015, 172, 3099-3111.	2.7	34
198	Negative Regulation of Leptin-induced Reactive Oxygen Species (ROS) Formation by Cannabinoid CB1 Receptor Activation in Hypothalamic Neurons. Journal of Biological Chemistry, 2015, 290, 13669-13677.	1.6	47

#	Article	IF	Citations
199	Effects of metabolites of the analgesic agent dipyrone (metamizol) on rostral ventromedial medulla cell activity in mice. European Journal of Pharmacology, 2015, 748, 115-122.	1.7	24
200	Discovery of non-electrophilic capsaicinoid-type TRPA1 ligands. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 1009-1011.	1.0	14
201	The endocannabinoid system in renal cells: regulation of <scp><scp>Na</scp></scp>⁺ transport by <scp>CB</scp>₁ receptors through distinct cell signalling pathways. British Journal of Pharmacology, 2015, 172, 4615-4625.	2.7	35
202	Deranged endocannabinoid responses to hedonic eating in underweight and recently weight-restored patients with anorexia nervosa. American Journal of Clinical Nutrition, 2015, 101, 262-269.	2.2	39
203	TRPV1 modulators: Synthesis and inÂvitro evaluation of 1-heteroaryl piperidinecarboxamide and piperazinylurea derivatives. European Journal of Medicinal Chemistry, 2015, 100, 129-138.	2.6	0
204	Two non-psychoactive cannabinoids reduce intracellular lipid levels and inhibit hepatosteatosis. Journal of Hepatology, 2015, 62, 1382-1390.	1.8	73
205	The ever-expanding world of the endocannabinoids: A concise introduction. , 2015, , xxv-xlv.		0
206	Distinct Temporal Fingerprint for Cyclic Adenosine Monophosphate (cAMP) Signaling of Indole-2-carboxamides as Allosteric Modulators of the Cannabinoid Receptors. Journal of Medicinal Chemistry, 2015, 58, 5979-5988.	2.9	28
207	Combining Mass Spectrometric Metabolic Profiling with Genomic Analysis: A Powerful Approach for Discovering Natural Products from Cyanobacteria. Journal of Natural Products, 2015, 78, 1671-1682.	1.5	156
208	Highly Selective, Reversible Inhibitor Identified by Comparative Chemoproteomics Modulates Diacylglycerol Lipase Activity in Neurons. Journal of the American Chemical Society, 2015, 137, 8851-8857.	6.6	49
209	A multi-target approach for pain treatment. Pain, 2015, 156, 890-903.	2.0	53
210	Role of the endocannabinoid system in obesity induced by neuropeptide Y overexpression in noradrenergic neurons. Nutrition and Diabetes, 2015, 5, e151-e151.	1.5	12
211	New quinolone- and 1,8-naphthyridine-3-carboxamides as selective CB2 receptor agonists with anticancer and immunoâ€“modulatory activity. European Journal of Medicinal Chemistry, 2015, 97, 10-18.	2.6	40
212	Changes in the endocannabinoid signaling system in CNS structures of TDP-43 transgenic mice: relevance for a neuroprotective therapy in TDP-43-related disorders. Journal of NeuroImmune Pharmacology, 2015, 10, 233-244.	2.1	44
213	Endocannabinoid signaling at the periphery: 50 years after THC. Trends in Pharmacological Sciences, 2015, 36, 277-296.	4.0	524
214	2-AG promotes the expression of conditioned fear via cannabinoid receptor type 1 on GABAergic neurons. Psychopharmacology, 2015, 232, 2811-2825.	1.5	91
215	Palmitoylethanolamide reduces pain-related behaviors and restores glutamatergic synapses homeostasis in the medial prefrontal cortex of neuropathic mice. Molecular Brain, 2015, 8, 47.	1.3	106
216	Fetal endocannabinoids orchestrate the organization of pancreatic islet microarchitecture. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E6185-94.	3.3	44

#	Article	IF	Citations
217	Inhibitory effect of positively charged triazine antagonists of prokineticin receptors on the transient receptor vanilloid type-1 (TRPV1) channel. Pharmacological Research, 2015, 99, 362-369.	3.1	6
218	Polypharmacology Shakes Hands with Complex Aetiopathology. Trends in Pharmacological Sciences, 2015, 36, 802-821.	4.0	29
219	Cannabinoids in the Treatment of Neurological Disorders. Neurotherapeutics, 2015, 12, 689-691.	2.1	7
220	The Endocannabinoid System and its Modulation by Phytocannabinoids. Neurotherapeutics, 2015, 12, 692-698.	2.1	281
221	Anandamide and decidual remodelling: COX-2 oxidative metabolism as a key regulator. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2015, 1851, 1473-1481.	1.2	17
222	N-Acyldopamines and N-Acylserotonins: From Synthetic Pharmacological Tools to Endogenous Multitarget Mediators. , 2015, , 67-84.		3
223	Endocannabinoid signalling and the deteriorating brain. Nature Reviews Neuroscience, 2015, 16, 30-42.	4.9	312
224	Are cannabidiol and Î”⁹â€tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review. British Journal of Pharmacology, 2015, 172, 737-753.	2.7	412
225	Placebo Effects in a Multiple Sclerosis Spasticity Enriched Clinical Trial with the Oromucosal Cannabinoid Spray (<scp>THC</scp>/<scp>CBD</scp>): Dimension and Possible Causes. CNS Neuroscience and Therapeutics, 2015, 21, 215-221.	1.9	10
226	Synthesis, biological activity and molecular modeling of new biphenylic carboxamides as potent and selective CB2 receptor ligands. European Journal of Medicinal Chemistry, 2015, 90, 526-536.	2.6	18
227	Protective Effect of Palmitoylethanolamide in a Rat Model of Cystitis. Journal of Urology, 2015, 193, 1401-1408.	0.2	28
228	Diacerein is a potent and selective inhibitor of palmitoylethanolamide inactivation with analgesic activity in a rat model of acute inflammatory pain. Pharmacological Research, 2015, 91, 9-14.	3.1	37
229	Adolescent exposure to THC in female rats disrupts developmental changes in the prefrontal cortex. Neurobiology of Disease, 2015, 73, 60-69.	2.1	150
230	Palmitoylethanolamide, a naturally occurring lipid, is an orally effective intestinal antiâ€inflammatory agent. British Journal of Pharmacology, 2015, 172, 142-158.	2.7	132
231	Editorial :. Recent Patents on CNS Drug Discovery, 2014, 9, 1-1.	0.9	93
232	Deficiency of cannabinoid receptor of type 2 worsens renal functional and structural abnormalities in streptozotocin-induced diabetic mice. Kidney International, 2014, 86, 979-990.	2.6	51
233	Fetal cannabinoid receptors and the "dis-joint-ed" brain. EMBO Journal, 2014, 33, 665-667.	3.5	17
234	The Endocannabinoid System â€“ Back to the Scene of Cardiometabolic Risk Factors Control?. Hormone and Metabolic Research, 2014, 46, 529-536.	0.7	14

#	Article	IF	Citations
235	Increased levels of palmitoylethanolamide and other bioactive lipid mediators and enhanced local mast cell proliferation in canine atopic dermatitis. BMC Veterinary Research, 2014, 10, 21.	0.7	35
236	Effect of narrowband ultraviolet B treatment on endocannabinoid plasma levels in patients with psoriasis. British Journal of Dermatology, 2014, 171, 198-201.	1.4	3
237	Prostamide <scp>F₂</scp>_{Î±} receptor antagonism combined with inhibition of <scp>FAAH </scp>may block the proâ€inflammatory mediators formed following selective <scp>FAAH</scp> inhibition. British Journal of Pharmacology, 2014, 171, 1408-1419.	2.7	21
238	Endocannabinoids and neuropathic pain: focus on neuronâ€“glia and endocannabinoidâ€“neurotrophin interactions. European Journal of Neuroscience, 2014, 39, 401-408.	1.2	55
239	1,2-Dihydro-2-oxopyridine-3-carboxamides: The C-5 substituent is responsible for functionality switch at CB2 cannabinoid receptor. European Journal of Medicinal Chemistry, 2014, 74, 524-532.	2.6	16
240	Palmitoylethanolamide normalizes intestinal motility in a model of postâ€inflammatory accelerated transit: involvement of <scp>CB</scp>₁ receptors and <scp>TRPV</scp>1 channels. British Journal of Pharmacology, 2014, 171, 4026-4037.	2.7	78
241	Effect of chirality and lipophilicity in the functional activity of evodiamine and its analogues at <scp>TRPV1</scp> channels. British Journal of Pharmacology, 2014, 171, 2608-2620.	2.7	19
242	Effect of acyclic monoterpene alcohols and their derivatives on TRP channels. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 5507-5511.	1.0	19
243	Naphthalene and 2,3-dihydrobenzo[b][1,4]dioxine derivatives with extended side chains as new scaffolds of CB2-selective ligands. MedChemComm, 2014, 5, 1571-1576.	3.5	5
244	New horizons on the role of cannabinoid CB1 receptors in palatable food intake, obesity and related dysmetabolism. International Journal of Obesity Supplements, 2014, 4, S26-S30.	12.5	19
245	Circulating endocannabinoids in insulin sensitive vs. Insulin resistant obese postmenopausal women. A MONET group study. Obesity, 2014, 22, 211-216.	1.5	43
246	Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia, 2014, 55, 791-802.	2.6	766
247	Mooreamide A: A Cannabinomimetic Lipid from the Marine Cyanobacterium Moorea bouillonii. Lipids, 2014, 49, 1127-1132.	0.7	20
248	CB2-Selective Cannabinoid Receptor Ligands: Synthesis, Pharmacological Evaluation, and Molecular Modeling Investigation of 1,8-Naphthyridin-2(1H)-one-3-carboxamides. Journal of Medicinal Chemistry, 2014, 57, 8777-8791.	2.9	46
249	Anandamide produced by Ca2+-insensitive enzymes induces excitation in primary sensory neurons. Pflugers Archiv European Journal of Physiology, 2014, 466, 1421-1435.	1.3	15
250	Nonpsychotropic Plant Cannabinoids, Cannabidivarin (CBDV) and Cannabidiol (CBD), Activate and Desensitize Transient Receptor Potential Vanilloid 1 (TRPV1) Channels in Vitro: Potential for the Treatment of Neuronal Hyperexcitability. ACS Chemical Neuroscience, 2014, 5, 1131-1141.	1.7	301
251	Endocannabinoids and energy homeostasis: An update. BioFactors, 2014, 40, 389-397.	2.6	103
252	Discovery of Glycine Sulfonamides as Dual Inhibitors of sn-1-Diacylglycerol Lipase Î± and Î±/Î²-Hydrolase Domain 6. Journal of Medicinal Chemistry, 2014, 57, 6610-6622.	2.9	28

#	Article	IF	Citations
253	Structureâ€“affinity relationships and pharmacological characterization of new alkyl-resorcinol cannabinoid receptor ligands: Identification of a dual cannabinoid receptor/TRPA1 channel agonist. Bioorganic and Medicinal Chemistry, 2014, 22, 4770-4783.	1.4	13
254	Glutamate spillover drives endocannabinoid production and inhibits GABAergic transmission in the Substantia Nigra pars compacta. Neuropharmacology, 2014, 79, 467-475.	2.0	19
255	The endocannabinoid system mediates aerobic exercise-induced antinociception in rats. Neuropharmacology, 2014, 77, 313-324.	2.0	65
256	The endocannabinoid 2-AG controls skeletal muscle cell differentiation via CB1 receptor-dependent inhibition of K _v 7 channels. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E2472-81.	3.3	75
257	The A1 adenosine receptor as a new player in microglia physiology. Glia, 2014, 62, 122-132.	2.5	86
258	The dual blocker of FAAH/TRPV1 N-arachidonoylserotonin reverses the behavioral despair induced by stress in rats and modulates the HPA-axis. Pharmacological Research, 2014, 87, 151-159.	3.1	66
259	Acute Resistance Exercise Induces Antinociception by Activation of the Endocannabinoid System in Rats. Anesthesia and Analgesia, 2014, 119, 702-715.	1.1	60
260	Iron overload causes osteoporosis in thalassemia major patients through interaction with transient receptor potential vanilloid type 1 (TRPV1) channels. Haematologica, 2014, 99, 1876-1884.	1.7	64
261	Care and Feeding of the Endocannabinoid System: A Systematic Review of Potential Clinical Interventions that Upregulate the Endocannabinoid System. PLoS ONE, 2014, 9, e89566.	1.1	121
262	Cannabinoids and Schizophrenia: Therapeutic Prospects. Current Pharmaceutical Design, 2014, 20, 2194-2204.	0.9	26
263	Rimonabant Precipitates Anxiety in Rats Withdrawn from Palatable Food: Role of the Central Amygdala. Neuropsychopharmacology, 2013, 38, 2498-2507.	2.8	54
264	Chronic treatment with krill powder reduces plasma triglyceride and anandamide levels in mildly obese men. Lipids in Health and Disease, 2013, 12, 78.	1.2	67
265	A novel fluorophosphonate inhibitor of the biosynthesis of the endocannabinoid 2â€arachidonoylglycerol with potential antiâ€obesity effects. British Journal of Pharmacology, 2013, 169, 784-793.	2.7	63
266	Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease. Biochemical Pharmacology, 2013, 85, 1306-1316.	2.0	237
267	Analogues of perillaketone as highly potent agonists of TRPA1 channel. Food Chemistry, 2013, 141, 2044-2051.	4.2	21
268	The administration of endocannabinoid uptake inhibitors OMDM-2 or VDM-11 promotes sleep and decreases extracellular levels of dopamine in rats. Physiology and Behavior, 2013, 109, 88-95.	1.0	22
269	Anandamide-derived Prostamide F2Î± Negatively Regulates Adipogenesis. Journal of Biological Chemistry, 2013, 288, 23307-23321.	1.6	43
270	The effect of cannabichromene on adult neural stem/progenitor cells. Neurochemistry International, 2013, 63, 432-437.	1.9	74

#	Article	IF	Citations
271	Some like it pungent and vile. TRPA1 as a molecular target for the malodorous vinyl disulfides from asafoetida. FÃ¬toterapÃ¬Ã¢, 2013, 90, 247-251.	1.1	22
272	The cannabinoid <scp>TRPA1</scp> agonist cannabichromene inhibits nitric oxide production in macrophages and ameliorates murine colitis. British Journal of Pharmacology, 2013, 169, 213-229.	2.7	135
273	Development of an Activityâ€Based Probe and In Silico Design Reveal Highly Selective Inhibitors for Diacylglycerol Lipaseâ€Îı± in Brain. Angewandte Chemie - International Edition, 2013, 52, 12081-12085.	7.2	73
274	3-Ylidenephthalides as a new class of transient receptor potential channel TRPA1 and TRPM8 modulators. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 5614-5618.	1.0	35
275	Endocannabinoid system and mood disorders: Priming a target for new therapies. , 2013, 138, 18-37.		187
276	Antiepileptic action of N-palmitoylethanolamine through CB1 and PPAR-Îı± receptor activation in a genetic model of absence epilepsy. Neuropharmacology, 2013, 69, 115-126.	2.0	91
277	Biaryl tetrazolyl ureas as inhibitors of endocannabinoid metabolism: Modulation at the N-portion and distal phenyl ring. European Journal of Medicinal Chemistry, 2013, 63, 118-132.	2.6	17
278	Piperazinyl carbamate fatty acid amide hydrolase inhibitors and transient receptor potential channel modulators as â€œdual-targetâ€•analgesics. Pharmacological Research, 2013, 76, 98-105.	3.1	29
279	CB1 Cannabinoid Receptors Couple to Focal Adhesion Kinase to Control Insulin Release. Journal of Biological Chemistry, 2013, 288, 32685-32699.	1.6	61
280	Analysis of the â€œendocannabinoidomeâ€•in peripheral tissues of obese Zucker rats. Prostaglandins Leukotrienes and Essential Fatty Acids, 2013, 89, 127-135.	1.0	41
281	Taste sensitivity to 6-n-propylthiouracil is associated with endocannabinoid plasma levels in normal-weight individuals. Nutrition, 2013, 29, 531-536.	1.1	32
282	Nonâ€THC cannabinoids inhibit prostate carcinoma growth in vitro and in vivo: proâ€apoptotic effects and underlying mechanisms. British Journal of Pharmacology, 2013, 168, 79-102.	2.7	166
283	Non-psychotropic analgesic drugs from the endocannabinoid system: â€œMagic bulletâ€•or â€œmultiple-targetâ€•strategies?. European Journal of Pharmacology, 2013, 716, 41-53.	1.7	34
284	The Endocannabinoid System in Energy Homeostasis and the Etiopathology of Metabolic Disorders. Cell Metabolism, 2013, 17, 475-490.	7.2	441
285	Platelet-Rich Plasma Exerts Antinociceptive Activity by a Peripheral Endocannabinoid-Related Mechanism. Tissue Engineering - Part A, 2013, 19, 2120-2129.	1.6	40
286	Impact of omegaâ€6 polyunsaturated fatty acid supplementation and Îłâ€aminobutyric acid on astrogliogenesis through the endocannabinoid system. Journal of Neuroscience Research, 2013, 91, 943-953.	1.3	5
287	Endocannabinoids: A unique opportunity to develop multitarget analgesics. Pain, 2013, 154, S87-S93.	2.0	83
288	Preparation and characterization of Î”⁹-tetrahydrocannabinol-loaded biodegradable polymeric microparticles and their antitumoral efficacy on cancer cell lines. Journal of Drug Targeting, 2013, 21, 710-718.	2.1	17

#	Article	IF	Citations
289	Tetrahydro-Î²-carboline derivatives targeting fatty acid amide hydrolase (FAAH) and transient receptor potential (TRP) channels. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 138-142.	1.0	13
290	Possible involvement of endocannabinoids in the increase of morphine consumption in maternally deprived rat. Neuropharmacology, 2013, 65, 193-199.	2.0	18
291	Synthesis and binding study of certain 6-arylalkanamides as molecular probes for cannabinoid receptor subtypes. Journal of Enzyme Inhibition and Medicinal Chemistry, 2013, 28, 436-439.	2.5	1
292	Improvement in coronary circulatory function in morbidly obese individuals after gastric bypass-induced weight loss: relation to alterations in endocannabinoids and adipocytokines. European Heart Journal, 2013, 34, 2063-2073.	1.0	90
293	Control of experimental spasticity by targeting the degradation of endocannabinoids using selective fatty acid amide hydrolase inhibitors. Multiple Sclerosis Journal, 2013, 19, 1896-1904.	1.4	34
294	Acute inhibition of diacylglycerol lipase blocks endocannabinoidâ€mediated retrograde signalling: evidence for onâ€demand biosynthesis of 2â€arachidonoylglycerol. Journal of Physiology, 2013, 591, 4765-4776.	1.3	50
295	The cannabinoid Î”9-tetrahydrocannabivarin (THCV) ameliorates insulin sensitivity in two mouse models of obesity. Nutrition and Diabetes, 2013, 3, e68-e68.	1.5	87
296	The inhibition of 2-arachidonoyl-glycerol (2-AG) biosynthesis, rather than enhancing striatal damage, protects striatal neurons from malonate-induced death: a potential role of cyclooxygenase-2-dependent metabolism of 2-AG. Cell Death and Disease, 2013, 4, e862-e862.	2.7	69
297	Obesity-driven synaptic remodeling affects endocannabinoid control of orexinergic neurons. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, E2229-38.	3.3	128
298	Editorial. Recent Patents on CNS Drug Discovery, 2013, 8, 1-1.	0.9	1
299	Editorial (Hot Topic: Palmitoylethanolamide: Biochemistry, Pharmacology and Therapeutic Use of a) Tj ETQq1 1 0.784314 rgBT /Overlock 4-6.	0.8	15
300	Role of Endocannabinoids and Cannabinoid-1 Receptors in Cerebrocortical Blood Flow Regulation. PLoS ONE, 2013, 8, e53390.	1.1	25
301	Full Inhibition of Spinal FAAH Leads to TRPV1-Mediated Analgesic Effects in Neuropathic Rats and Possible Lipoxygenase-Mediated Remodeling of Anandamide Metabolism. PLoS ONE, 2013, 8, e60040.	1.1	84
302	The Cannabinoid Receptor Type 2 as Mediator of Mesenchymal Stromal Cell Immunosuppressive Properties. PLoS ONE, 2013, 8, e80022.	1.1	33
303	Temperature-Sensitive Transient Receptor Potential Channels as Ionotropic Cannabinoid Receptors. , 2013, , 175-197.		1
304	TRPV1-Dependent and -Independent Alterations in the Limbic Cortex of Neuropathic Mice: Impact on Glial Caspases and Pain Perception. Cerebral Cortex, 2012, 22, 2495-2518.	1.6	88
305	The activation of the cannabinoid receptor type 2 reduces neutrophilic protease-mediated vulnerability in atherosclerotic plaques. European Heart Journal, 2012, 33, 846-856.	1.0	81
306	The â€˜headache treeâ€™ via umbellulone and TRPA1 activates the trigeminovascular system. Brain, 2012, 135, 376-390.	3.7	163

#	Article	IF	Citations
307	Evaluation of the endogenous cannabinoid system in mediating the behavioral effects of dipyrone (metamizol) in mice. Behavioural Pharmacology, 2012, 23, 722-726.	0.8	21
308	2-Arylbenzofuran-based molecules as multipotent Alzheimer's disease modifying agents. European Journal of Medicinal Chemistry, 2012, 58, 519-532.	2.6	56
309	Investigations on the 4-quinolone-3-carboxylic acid motif. 6. Synthesis and pharmacological evaluation of 7-substituted quinolone-3-carboxamide derivatives as high affinity ligands for cannabinoid receptors. European Journal of Medicinal Chemistry, 2012, 58, 30-43.	2.6	24
310	The role of the endocannabinoid system in skeletal muscle and metabolic adaptations to exercise: potential implications for the treatment of obesity. Obesity Reviews, 2012, 13, 1110-1124.	3.1	63
311	Endocannabinoids in Amygdala and Nucleus Accumbens Mediate Social Play Reward in Adolescent Rats. Journal of Neuroscience, 2012, 32, 14899-14908.	1.7	144
312	Second generation CB1 receptor blockers and other inhibitors of peripheral endocannabinoid overactivity and the rationale of their use against metabolic disorders. Expert Opinion on Investigational Drugs, 2012, 21, 1309-1322.	1.9	70
313	The First Dual ChE/FAAH Inhibitors: New Perspectives for Alzheimer's Disease?. ACS Medicinal Chemistry Letters, 2012, 3, 182-186.	1.3	38
314	â€œRedundancyâ€•of Endocannabinoid Inactivation: New Challenges and Opportunities for Pain Control. ACS Chemical Neuroscience, 2012, 3, 356-363.	1.7	70
315	Spinal anandamide produces analgesia in neuropathic rats: Possible CB1- and TRPV1-mediated mechanisms. Neuropharmacology, 2012, 62, 1746-1755.	2.0	63
316	At the heart of the matter: the endocannabinoid system in cardiovascular function and dysfunction. Trends in Pharmacological Sciences, 2012, 33, 331-340.	4.0	132
317	Inhibitory effect of cannabichromene, a major nonâ€psychotropic cannabinoid extracted from Cannabis sativa, on inflammationâ€induced hypermotility in mice. British Journal of Pharmacology, 2012, 166, 1444-1460.	2.7	131
318	Chronic blockade of CB₁ receptors reverses startle gating deficits and associated neurochemical alterations in rats reared in isolation. British Journal of Pharmacology, 2012, 167, 1652-1664.	2.7	12
319	A reâ€evaluation of 9â€<scp>HODE</scp> activity at <scp>TRPV</scp>1 channels in comparison with anandamide: enantioselectivity and effects at other <scp>TRP</scp> channels and in sensory neurons. British Journal of Pharmacology, 2012, 167, 1643-1651.	2.7	42
320	Cannabinoid receptor type 1 and 2 expression in the skin of healthy dogs and dogs with atopic dermatitis. American Journal of Veterinary Research, 2012, 73, 988-995.	0.3	64
321	â€œDe-liver-anceâ€•From CB1: A Way to Counteract Insulin Resistance?. Gastroenterology, 2012, 142, 1063-1066.	0.6	6
322	Coronary Vasomotor Control in Obesity and Morbid Obesity. JACC: Cardiovascular Imaging, 2012, 5, 805-815.	2.3	69
323	Inhibitors of endocannabinoid breakdown for pain: Not so FA(AH)cile, after all. Pain, 2012, 153, 1785-1786.	2.0	32
324	Kavalactones and the endocannabinoid system: The plant-derived yangonin is a novel CB1 receptor ligand. Pharmacological Research, 2012, 66, 163-169.	3.1	45

#	Article	IF	Citations
325	Palvanil, a non-pungent capsaicin analogue, inhibits inflammatory and neuropathic pain with little effects on bronchopulmonary function and body temperature. Pharmacological Research, 2012, 66, 243-250.	3.1	18
326	Why do cannabinoid receptors have more than one endogenous ligand?. Philosophical Transactions of the Royal Society B: Biological Sciences, 2012, 367, 3216-3228.	1.8	241
327	Endocannabinoids in nervous system health and disease: the big picture in a nutshell. Philosophical Transactions of the Royal Society B: Biological Sciences, 2012, 367, 3193-3200.	1.8	83
328	Leucettamols, Bifunctionalized Marine Sphingoids, Act as Modulators of TRPA1 and TRPM8 Channels. Marine Drugs, 2012, 10, 2435-2447.	2.2	19
329	Indole-2-carboxamides as Allosteric Modulators of the Cannabinoid CB1 Receptor. Journal of Medicinal Chemistry, 2012, 55, 5627-5631.	2.9	54
330	Design, Synthesis, and Pharmacological Characterization of Indol-3-ylacetamides, Indol-3-yloxoacetamides, and Indol-3-ylcarboxamides: Potent and Selective CB2 Cannabinoid Receptor Inverse Agonists. Journal of Medicinal Chemistry, 2012, 55, 5391-5402.	2.9	27
331	Hedonic Eating Is Associated with Increased Peripheral Levels of Ghrelin and the Endocannabinoid 2-Arachidonoyl-Glycerol in Healthy Humans: A Pilot Study. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E917-E924.	1.8	135
332	Neural precursor cells induce cell death of high-grade astrocytomas through stimulation of TRPV1. Nature Medicine, 2012, 18, 1232-1238.	15.2	159
333	Sesquiterpenoids from Common Ragweed (Ambrosia artemisiifolia L.), an Invasive Biological Polluter. European Journal of Organic Chemistry, 2012, 2012, 5162-5170.	1.2	24
334	Investigations on the 4â€Quinoloneâ€3â€Carboxylic Acid Motif Partâ€…5: Modulation of the Physicochemical Profile of a Set of Potent and Selective Cannabinoidâ€2 Receptor Ligands through a Bioisosteric Approach. ChemMedChem, 2012, 7, 920-934.	1.6	27
335	Chemopreventive effect of the non-psychotropic phytocannabinoid cannabidiol on experimental colon cancer. Journal of Molecular Medicine, 2012, 90, 925-934.	1.7	146
336	Modulation of mouse gastrointestinal motility by allyl isothiocyanate, a constituent of cruciferous vegetables (Brassicaceae): evidence for TRPA1â€independent effects. British Journal of Pharmacology, 2012, 165, 1966-1977.	2.7	48
337	Cannabinoid actions at TRPV channels: effects on TRPV3 and TRPV4 and their potential relevance to gastrointestinal inflammation. Acta Physiologica, 2012, 204, 255-266.	1.8	246
338	Rational design, synthesis and anti-proliferative properties of new CB2 selective cannabinoid receptor ligands: An investigation of the 1,8-naphthyridin-2(1H)-one scaffold. European Journal of Medicinal Chemistry, 2012, 52, 284-294.	2.6	50
339	Effects of intra-ventrolateral periaqueductal grey palmitoylethanolamide on thermoceptive threshold and rostral ventromedial medulla cell activity. European Journal of Pharmacology, 2012, 676, 41-50.	1.7	51
340	Novel bioactive metabolites of dipyrone (metamizol). Bioorganic and Medicinal Chemistry, 2012, 20, 101-107.	1.4	102
341	Synthesis and biological evaluation of [6]-gingerol analogues as transient receptor potential channel TRPV1 and TRPA1 modulators. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 1674-1677.	1.0	66
342	Modulation of thermo-transient receptor potential (thermo-TRP) channels by thymol-based compounds. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 3535-3539.	1.0	25

#	Article	IF	Citations
343	Intense exercise increases circulating endocannabinoid and BDNF levels in humansâ€"Possible implications for reward and depression. Psychoneuroendocrinology, 2012, 37, 844-851.	1.3	340
344	Effects of palmitoylethanolamide on the cutaneous allergic inflammatory response in Ascaris hypersensitive Beagle dogs. Veterinary Journal, 2012, 191, 377-382.	0.6	31
345	Poly-Îµ-caprolactone microspheres as a drug delivery system for cannabinoid administration: Development, characterization and in vitro evaluation of their antitumoral efficacy. Journal of Controlled Release, 2012, 161, 927-932.	4.8	89
346	Discovery of Prostamide F2Î± and Its Role in Inflammatory Pain and Dorsal Horn Nociceptive Neuron Hyperexcitability. PLoS ONE, 2012, 7, e31111.	1.1	91
347	Questions & Answers. Expert Review of Neurotherapeutics, 2011, 11, 21-22.	1.4	0
348	Anandamide-loaded nanoparticles: Preparation and characterization. Journal of Microencapsulation, 2011, 28, 200-210.	1.2	8
349	Cannabinoid CB1 receptor antagonism prevents neurochemical and behavioural deficits induced by chronic phencyclidine. International Journal of Neuropsychopharmacology, 2011, 14, 17-28.	1.0	45
350	N-palmitoyl-vanillamide (palvanil) is a non-pungent analogue of capsaicin with stronger desensitizing capability against the TRPV1 receptor and anti-hyperalgesic activity. Pharmacological Research, 2011, 63, 294-299.	3.1	32
351	Endocannabinoid pathways and their role in multiple sclerosis-related muscular dysfunction. Expert Review of Neurotherapeutics, 2011, 11, 9-14.	1.4	5
352	Bioactive Prenylogous Cannabinoid from Fiber Hemp (Cannabis sativa). Journal of Natural Products, 2011, 74, 2019-2022.	1.5	61
353	Cannabinomimetic Lipid from a Marine Cyanobacterium. Journal of Natural Products, 2011, 74, 2313-2317.	1.5	36
354	The endovanilloid/endocannabinoid system: A new potential target for osteoporosis therapy. Bone, 2011, 48, 997-1007.	1.4	55
355	Cannabinoids and Endocannabinoids in Metabolic Disorders with Focus on Diabetes. Handbook of Experimental Pharmacology, 2011, , 75-104.	0.9	94
356	Investigations on the 4-Quinolone-3-carboxylic Acid Motif. 4. Identification of New Potent and Selective Ligands for the Cannabinoid Type 2 Receptor with Diverse Substitution Patterns and Antihyperalgesic Effects in Mice. Journal of Medicinal Chemistry, 2011, 54, 5444-5453.	2.9	52
357	Desulfohaplosamate, a new phosphate-containing steroid from Dasychalina sp., is a selective cannabinoid CB2 receptor ligand. Steroids, 2011, 76, 998-1002.	0.8	20
358	Alteration of the endocannabinoid system in mouse brain during prion disease. Neuroscience, 2011, 177, 292-297.	1.1	4
359	Endocannabinoids Generated by Ca2+ or by Metabotropic Glutamate Receptors Appear to Arise from Different Pools of Diacylglycerol Lipase. PLoS ONE, 2011, 6, e16305.	1.1	35
360	Gut feelings about the endocannabinoid system. Neurogastroenterology and Motility, 2011, 23, 391-398.	1.6	23

#	Article	IF	Citations
361	Nonâ€psychoactive cannabinoids modulate the descending pathway of antinociception in anaesthetized rats through several mechanisms of action. British Journal of Pharmacology, 2011, 162, 584-596.	2.7	130
362	Effects of cannabinoids and cannabinoidâ€enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. British Journal of Pharmacology, 2011, 163, 1479-1494.	2.7	700
363	Endocannabinoid signaling in the brain: biosynthetic mechanisms in the limelight. Nature Neuroscience, 2011, 14, 9-15.	7.1	147
364	Why fasting worms age slowly. Nature, 2011, 473, 161-162.	13.7	11
365	Palmitoylethanolamide counteracts reactive astrogliosis induced by Î²-amyloid peptide. Journal of Cellular and Molecular Medicine, 2011, 15, 2664-2674.	1.6	90
366	Homology modeling in tandem with 3D-QSAR analyses: A computational approach to depict the agonist binding site of the human CB2 receptor. European Journal of Medicinal Chemistry, 2011, 46, 4489-4505.	2.6	36
367	1-Aryl-5-(1H-pyrrol-1-yl)-1H-pyrazole-3-carboxamide: An effective scaffold for the design of either CB1 or CB2 receptor ligands. European Journal of Medicinal Chemistry, 2011, 46, 5641-5653.	2.6	15
368	Resorcinol-sn-Glycerol Derivatives: Novel 2-Arachidonoylglycerol Mimetics Endowed with High Affinity and Selectivity for Cannabinoid Type 1 Receptor. Journal of Medicinal Chemistry, 2011, 54, 8278-8288.	2.9	6
369	Peripheral effects of the endocannabinoid system in energy homeostasis: Adipose tissue, liver and skeletal muscle. Reviews in Endocrine and Metabolic Disorders, 2011, 12, 153-162.	2.6	74
370	Inhibition of basal and ultraviolet B-induced melanogenesis by cannabinoid CB1 receptors: a keratinocyte-dependent effect. Archives of Dermatological Research, 2011, 303, 201-210.	1.1	32
371	Altered endocannabinoid signalling after a high-fat diet in Apoe â^'/â^' mice: relevance to adipose tissue inflammation, hepatic steatosis and insulin resistance. Diabetologia, 2011, 54, 2900-2910.	2.9	67
372	Effect of the Cannabinoid Receptor-1 antagonist SR141716A on human adipocyte inflammatory profile and differentiation. Journal of Inflammation, 2011, 8, 33.	1.5	27
373	Effect of dietary krill oil supplementation on the endocannabinoidome of metabolically relevant tissues from high-fat-fed mice. Nutrition and Metabolism, 2011, 8, 51.	1.3	123
374	Krill oil significantly decreases 2-arachidonoylglycerol plasma levels in obese subjects. Nutrition and Metabolism, 2011, 8, 7.	1.3	89
375	The Blockade of the Transient Receptor Potential Vanilloid Type 1 and Fatty Acid Amide Hydrolase Decreases Symptoms and Central Sequelae in the Medial Prefrontal Cortex of Neuropathic Rats. Molecular Pain, 2011, 7, 1744-8069-7-7.	1.0	75
376	An NMR Spectroscopic Method to Identify and Classify Thiolâ€Trapping Agents: Revival of Michael Acceptors for Drug Discovery?. Angewandte Chemie - International Edition, 2011, 50, 467-471.	7.2	143
377	Three-dimensional quantitative structureâ€“selectivity relationships analysis guided rational design of a highly selective ligand for the cannabinoid receptor 2. European Journal of Medicinal Chemistry, 2011, 46, 547-555.	2.6	31
378	Endocannabinoids: An appetite for fat. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 12567-12568.	3.3	32

#	Article	IF	Citations
379	Elevated endocannabinoid plasma levels are associated with coronary circulatory dysfunction in obesity. European Heart Journal, 2011, 32, 1369-1378.	1.0	123
380	Protective Role of Cannabinoid Receptor Type 2 in a Mouse Model of Diabetic Nephropathy. Diabetes, 2011, 60, 2386-2396.	0.3	123
381	Endocannabinoid Modulation in the Olfactory Epithelium. Results and Problems in Cell Differentiation, 2011, 52, 139-145.	0.2	21
382	Mechanisms of the Anti-Obesity Effects of Oxytocin in Diet-Induced Obese Rats. PLoS ONE, 2011, 6, e25565.	1.1	211
383	Protective role of palmitoylethanolamide in contact allergic dermatitis. Allergy: European Journal of Allergy and Clinical Immunology, 2010, 65, 698-711.	2.7	104
384	Circulating and hepatic endocannabinoids and endocannabinoid-related molecules in patients with cirrhosis. Liver International, 2010, 30, 816-825.	1.9	69
385	Chemical characterisation of oxidative degradation products of Î”9-THC. Tetrahedron, 2010, 66, 9497-9501.	1.0	30
386	Enantioselective synthesis of 3(S)-hydroxy polygodial derivatives and evaluation of their vanilloid activity. Tetrahedron, 2010, 66, 9785-9789.	1.0	12
387	Non-CB1, Non-CB2 Receptors for Endocannabinoids, Plant Cannabinoids, and Synthetic Cannabimimetics: Focus on G-protein-coupled Receptors and Transient Receptor Potential Channels. Journal of NeuroImmune Pharmacology, 2010, 5, 103-121.	2.1	182
388	Cannabinoid CB1 receptor expression in relation to visceral adipose depots, endocannabinoid levels, microvascular damage, and the presence of the Cnr1 A3813G variant in humans. Metabolism: Clinical and Experimental, 2010, 59, 734-741.	1.5	42
389	An endocannabinoid tone limits excitotoxicity in vitro and in a model of multiple sclerosis. Neurobiology of Disease, 2010, 37, 166-176.	2.1	82
390	Anandamide and AM251, via water, modulate food intake at central and peripheral level in fish. General and Comparative Endocrinology, 2010, 166, 259-267.	0.8	31
391	Cannabimovone, a Cannabinoid with a Rearranged Terpenoid Skeleton from Hemp. European Journal of Organic Chemistry, 2010, 2010, 2067-2072.	1.2	60
392	Effect of dietary fat on endocannabinoids and related mediators: Consequences on energy homeostasis, inflammation and mood. Molecular Nutrition and Food Research, 2010, 54, 82-92.	1.5	68
393	Synthesis and biological evaluation of new potential inhibitors of N-acylethanolamine hydrolyzing acid amidase. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 1210-1213.	1.0	46
394	(â˜')-Menthylamine derivatives as potent and selective antagonists of transient receptor potential melastatin type-8 (TRPM8) channels. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 2729-2732.	1.0	36
395	Synthesis and biological evaluation of new N-alkyl 1-aryl-5-(1H-pyrrol-1-yl)-1H-pyrazole-3-carboxamides as cannabinoid receptor ligands. European Journal of Medicinal Chemistry, 2010, 45, 5878-5886.	2.6	7
396	Phytocannabinoids beyond the Cannabis plant â€“ do they exist?. British Journal of Pharmacology, 2010, 160, 523-529.	2.7	169

#	Article	IF	Citations
397	The plant cannabinoid Î”⁹â€tetrahydrocannabivarin can decrease signs of inflammation and inflammatory pain in mice. British Journal of Pharmacology, 2010, 160, 677-687.	2.7	112
398	Basal and Fasting/Refeedingâ€regulated Tissue Levels of Endogenous PPARâ€Î± Ligands in Zucker Rats. Obesity, 2010, 18, 55-62.	1.5	65
399	Anandamide serves two masters in the brain. Nature Neuroscience, 2010, 13, 1446-1448.	7.1	33
400	Cannabinoid Receptors and Endocannabinoids: Role in Neuroinflammatory and Neurodegenerative Disorders. CNS and Neurological Disorders - Drug Targets, 2010, 9, 564-573.	0.8	134
401	Exploiting Nanotechnologies and TRPV1 Channels to Investigate the Putative Anandamide Membrane Transporter. PLoS ONE, 2010, 5, e10239.	1.1	33
402	A Gradient of 2-Arachidonoylglycerol Regulates Mouse Epididymal Sperm Cell Start-Up1. Biology of Reproduction, 2010, 82, 451-458.	1.2	77
403	Diacylglycerol Lipase Is Not Involved in Depolarization-Induced Suppression of Inhibition at Unitary Inhibitory Connections in Mouse Hippocampus. Journal of Neuroscience, 2010, 30, 2710-2715.	1.7	34
404	Cannabinoid Receptor 1 Blockade Ameliorates Albuminuria in Experimental Diabetic Nephropathy. Diabetes, 2010, 59, 1046-1054.	0.3	130
405	The Endocannabinoid 2-Arachidonoyl-Glycerol Controls Odor Sensitivity in Larvae of Xenopus laevis. Journal of Neuroscience, 2010, 30, 8965-8973.	1.7	50
406	DAG Lipase Involvement in Depolarization-Induced Suppression of Inhibition: Does Endocannabinoid Biosynthesis Always Meet the Demand?. Neuroscientist, 2010, 16, 608-613.	2.6	38
407	Endocannabinoids as Regulators of Transient Receptor Potential (TRP)Channels: a Further Opportunity to Develop New Endocannabinoid-Based Therapeutic Drugs. Current Medicinal Chemistry, 2010, 17, 1430-1449.	1.2	184
408	Maternal Dietary Fat Determines Metabolic Profile and the Magnitude of Endocannabinoid Inhibition of the Stress Response in Neonatal Rat Offspring. Endocrinology, 2010, 151, 1685-1694.	1.4	63
409	The Levels of the Endocannabinoid Receptor CB2 and Its Ligand 2-Arachidonoylglycerol Are Elevated in Endometrial Carcinoma. Endocrinology, 2010, 151, 921-928.	1.4	75
410	Investigations on the 4-Quinolone-3-carboxylic Acid Motif. 3. Synthesis, Structureâ€'Affinity Relationships, and Pharmacological Characterization of 6-Substituted 4-Quinolone-3-carboxamides as Highly Selective Cannabinoid-2 Receptor Ligands. Journal of Medicinal Chemistry, 2010, 53, 5915-5928.	2.9	43
411	Novel mechanisms in obesity, type 2 diabetes and accompanying inflammation: focus on lipid signaling. Drug Discovery Today Disease Mechanisms, 2010, 7, e159-e161.	0.8	0
412	Levels of endocannabinoids and palmitoylethanolamide and their pharmacological manipulation in chronic granulomatous inflammation in rats. Pharmacological Research, 2010, 61, 321-328.	3.1	56
413	In vitro and in vivo pharmacological characterization of two novel selective cannabinoid CB2 receptor inverse agonists. Pharmacological Research, 2010, 61, 349-354.	3.1	27
414	The dual fatty acid amide hydrolase/TRPV1 blocker, N-arachidonoyl-serotonin, relieves carrageenan-induced inflammation and hyperalgesia in mice. Pharmacological Research, 2010, 61, 537-546.	3.1	57

#	Article	IF	Citations
415	Enhanced cognitive performance of dopamine D3 receptor â€œknock-outâ€•mice in the step-through passive-avoidance test: Assessing the role of the endocannabinoid/endovanilloid systems. Pharmacological Research, 2010, 61, 531-536.	3.1	52
416	Dietary krill oil increases docosahexaenoic acid and reduces 2-arachidonoylglycerol but not N-acylethanolamine levels in the brain of obese Zucker rats. International Dairy Journal, 2010, 20, 231-235.	1.5	76
417	N-palmitoyl-ethanolamine: Biochemistry and new therapeutic opportunities. Biochimie, 2010, 92, 724-727.	1.3	130
418	International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid Receptors and Their Ligands: Beyond CB₁and CB₂. Pharmacological Reviews, 2010, 62, 588-631.	7.1	1,425
419	Possible Anandamide and Palmitoylethanolamide involvement in human stroke. Lipids in Health and Disease, 2010, 9, 47.	1.2	45
420	Differential alterations of the concentrations of endocannabinoids and related lipids in the subcutaneous adipose tissue of obese diabetic patients. Lipids in Health and Disease, 2010, 9, 43.	1.2	71
421	FAAH and MAGL inhibitors: therapeutic opportunities from regulating endocannabinoid levels. Current Opinion in Investigational Drugs, 2010, 11, 51-62.	2.3	92
422	Endocannabinoids May Mediate the Ability of (n-3) Fatty Acids to Reduce Ectopic Fat and Inflammatory Mediators in Obese Zucker Rats. Journal of Nutrition, 2009, 139, 1495-1501.	1.3	210
423	CB1 antagonists for obesityâ€”what lessons have we learned from rimonabant?. Nature Reviews Endocrinology, 2009, 5, 633-638.	4.3	121
424	The endocannabinoid system and pivotal role of the CB ₂ receptor in mouse spermatogenesis. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 11131-11136.	3.3	118
425	Functional Interaction Between TRPV1 and Î¼-Opioid Receptors in the Descending Antinociceptive Pathway Activates Glutamate Transmission and Induces Analgesia. Journal of Neurophysiology, 2009, 101, 2411-2422.	0.9	50
426	Chemical synthesis, pharmacological characterization, and possible formation in unicellular fungi of 3-hydroxy-anandamide. Journal of Lipid Research, 2009, 50, 658-666.	2.0	9
427	Role of insulin as a negative regulator of plasma endocannabinoid levels in obese and nonobese subjects. European Journal of Endocrinology, 2009, 161, 715-722.	1.9	100
428	The endocannabinoid system is modulated in response to spinal cord injury in rats. Neurobiology of Disease, 2009, 33, 57-71.	2.1	107
429	Altered responses of dopamine D3 receptor null mice to excitotoxic or anxiogenic stimuli: Possible involvement of the endocannabinoid and endovanilloid systems. Neurobiology of Disease, 2009, 36, 70-80.	2.1	40
430	Adelmidrol, a palmitoylethanolamide analogue, reduces chronic inflammation in a carrageeninâ€granuloma model in rats. Journal of Cellular and Molecular Medicine, 2009, 13, 1086-1095.	1.6	39
431	Cannabinoid CB1 receptor elevation of intracellular calcium in neuroblastoma SH-SY5Y cells: Interactions with muscarinic and Î´-opioid receptors. Biochimica Et Biophysica Acta - Molecular Cell Research, 2009, 1793, 1289-1303.	1.9	27
432	Role of endocannabinoids and endovanilloids in Ca2+ signalling. Cell Calcium, 2009, 45, 611-624.	1.1	61

#	Article	IF	Citations
433	Synthesis and Pharmacological Activity of a Potent Inhibitor of the Biosynthesis of the Endocannabinoid 2â€Arachidonoylglycerol. ChemMedChem, 2009, 4, 946-950.	1.6	48
434	Lipidomic methodologies applicable to the study of endocannabinoids and related compounds: Endocannabinoidomics. European Journal of Lipid Science and Technology, 2009, 111, 53-63.	1.0	16
435	Cannabidiol, a safe and non-psychotropic ingredient of the marijuana plant Cannabis sativa, is protective in a murine model of colitis. Journal of Molecular Medicine, 2009, 87, 1111-1121.	1.7	156
436	Changes in plasma endocannabinoid levels in viscerally obese men following a 1Âyear lifestyle modification programme and waist circumference reduction: associations with changes in metabolic risk factors. Diabetologia, 2009, 52, 213-217.	2.9	173
437	TRPV1 channels control synaptic plasticity in the developing superior colliculus. Journal of Physiology, 2009, 587, 2521-2535.	1.3	85
438	The endocannabinoid system as a link between homoeostatic and hedonic pathways involved in energy balance regulation. International Journal of Obesity, 2009, 33, S18-S24.	1.6	152
439	Antiâ€inflammatory Effect of Palmitoylethanolamide on Human Adipocytes. Obesity, 2009, 17, 431-438.	1.5	56
440	Peripheral endocannabinoid dysregulation in obesity: relation to intestinal motility and energy processing induced by food deprivation and reâ€feeding. British Journal of Pharmacology, 2009, 158, 451-461.	2.7	141
441	From endocannabinoid profiling to â€˜endocannabinoid therapeuticsâ€™. Current Opinion in Chemical Biology, 2009, 13, 321-331.	2.8	71
442	Endocannabinoid chemical biology: a tool for the development of novel therapies. Current Opinion in Chemical Biology, 2009, 13, 309-320.	2.8	47
443	Synthesis and biological evaluation of piperazinyl carbamates and ureas as fatty acid amide hydrolase (FAAH) and transient receptor potential (TRP) channel dual ligands. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 6806-6809.	1.0	33
444	Conformationally Constrained Fatty Acid Ethanolamides as Cannabinoid and Vanilloid Receptor Probes. Journal of Medicinal Chemistry, 2009, 52, 3001-3009.	2.9	17
445	Rapid Combinatorial Access to a Library of 1,5-Disubstituted-3-indole-N-alkylacetamides as CB2 Receptor Ligands. ACS Combinatorial Science, 2009, 11, 795-798.	3.3	16
446	The endovanilloid/endocannabinoid system in human osteoclasts: Possible involvement in bone formation and resorption. Bone, 2009, 44, 476-484.	1.4	132
447	Development of a potent inhibitor of 2-arachidonoylglycerol hydrolysis with antinociceptive activity in vivo. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2009, 1791, 53-60.	1.2	65
448	Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends in Pharmacological Sciences, 2009, 30, 515-527.	4.0	717
449	The biosynthesis of N-arachidonoyl dopamine (NADA), a putative endocannabinoid and endovanilloid, via conjugation of arachidonic acid with dopamine. Prostaglandins Leukotrienes and Essential Fatty Acids, 2009, 81, 291-301.	1.0	66
450	New Resorcinolâ€'Anandamide â€œHybridsâ€•as Potent Cannabinoid Receptor Ligands Endowed with Antinociceptive Activity in Vivo. Journal of Medicinal Chemistry, 2009, 52, 2506-2514.	2.9	19

#	Article	IF	Citations
451	An introduction to the endocannabinoid system: from the early to the latest concepts. Best Practice and Research in Clinical Endocrinology and Metabolism, 2009, 23, 1-15.	2.2	203
452	The endocannabinoid system in metabolic control: a preface. Best Practice and Research in Clinical Endocrinology and Metabolism, 2009, 23, vii-ix.	2.2	4
453	Rational Design, Synthesis, and Pharmacological Properties of New 1,8-Naphthyridin-2(1H)-on-3-Carboxamide Derivatives as Highly Selective Cannabinoid-2 Receptor Agonists. Journal of Medicinal Chemistry, 2009, 52, 3644-3651.	2.9	36
454	Anxiolytic Effects in Mice of a Dual Blocker of Fatty Acid Amide Hydrolase and Transient Receptor Potential Vanilloid Type-1 Channels. Neuropsychopharmacology, 2009, 34, 593-606.	2.8	182
455	Regulation and possible role of endocannabinoids and related mediators in hypercholesterolemic mice with atherosclerosis. Atherosclerosis, 2009, 205, 433-441.	0.4	67
456	The endocannabinoid system: Its general strategy of action, tools for its pharmacological manipulation and potential therapeutic exploitation. Pharmacological Research, 2009, 60, 77-84.	3.1	326
457	Involvement of the endocannabinoid system in phencyclidine-induced cognitive deficits modelling schizophrenia. International Journal of Neuropsychopharmacology, 2009, 12, 599.	1.0	81
458	Increased endocannabinoid levels reduce the development of precancerous lesions in the mouse colon. Journal of Molecular Medicine, 2008, 86, 89-98.	1.7	108
459	Inhibitory effect of the anorexic compound oleoylethanolamide on gastric emptying in control and overweight mice. Journal of Molecular Medicine, 2008, 86, 413-422.	1.7	65
460	The endocannabinoid system in obesity and type 2 diabetes. Diabetologia, 2008, 51, 1356-1367.	2.9	245
461	Levels, Metabolism, and Pharmacological Activity of Anandamide in CB1 Cannabinoid Receptor Knockout Mice. Journal of Neurochemistry, 2008, 75, 2434-2444.	2.1	355
462	Phosphatidic Acid as the Biosynthetic Precursor of the Endocannabinoid 2-Arachidonoylglycerol in Intact Mouse Neuroblastoma Cells Stimulated with Ionomycin. Journal of Neurochemistry, 2008, 72, 2113-2119.	2.1	142
463	Dopamides, Vanillylamides, Ethanolamides, and Arachidonic Acid Amides of Antiâ€inflammatory and Analgesic Drug Substances as TRPV1 Ligands. ChemMedChem, 2008, 3, 1956-1964.	1.6	17
464	Genderâ€dependent cellular and biochemical effects of maternal deprivation on the hippocampus of neonatal rats: A possible role for the endocannabinoid system. Developmental Neurobiology, 2008, 68, 1334-1347.	1.5	80
465	Neuronal and glial alterations in the cerebellar cortex of maternally deprived rats: Gender differences and modulatory effects of two inhibitors of endocannabinoid inactivation. Developmental Neurobiology, 2008, 68, 1429-1440.	1.5	38
466	Carbamoyl tetrazoles as inhibitors of endocannabinoid inactivation: A critical revisitation. European Journal of Medicinal Chemistry, 2008, 43, 62-72.	2.6	59
467	New tetrazole-based selective anandamide uptake inhibitors. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 2820-2824.	1.0	31
468	Rimonabant in rats with a metabolic syndrome: good news after the depression. British Journal of Pharmacology, 2008, 154, 915-917.	2.7	19

#	Article	IF	Citations
469	Inhibitory effect of salvinorin A, from Salvia divinorum, on ileitisâ€induced hypermotility: crossâ€talk between Îºâ€opioid and cannabinoid CB₁ receptors. British Journal of Pharmacology, 2008, 155, 681-689.	2.7	72
470	Antinociceptive effects of tetrazole inhibitors of endocannabinoid inactivation: cannabinoid and nonâ€cannabinoid receptorâ€mediated mechanisms. British Journal of Pharmacology, 2008, 155, 775-782.	2.7	32
471	Endocannabinoid Dysregulation in the Pancreas and Adipose Tissue of Mice Fed With a Highâ€fat Diet. Obesity, 2008, 16, 553-565.	1.5	172
472	The role of endocannabinoids in the regulation of gastric emptying: alterations in mice fed a highâ€fat diet. British Journal of Pharmacology, 2008, 153, 1272-1280.	2.7	97
473	Why endocannabinoids are not all alike. Nature Neuroscience, 2008, 11, 124-126.	7.1	33
474	Targeting the endocannabinoid system: to enhance or reduce?. Nature Reviews Drug Discovery, 2008, 7, 438-455.	21.5	701
475	Study of the regulation of the endocannabinoid system in a virus model of multiple sclerosis reveals a therapeutic effect of palmitoylethanolamide. European Journal of Neuroscience, 2008, 28, 633-641.	1.2	103
476	Endocannabinoids: Some Like it Fat (and Sweet Too). Journal of Neuroendocrinology, 2008, 20, 100-109.	1.2	40
477	The CB1 cannabinoid receptor antagonist AM251 attenuates amphetamine-induced behavioural sensitization while causing monoamine changes in nucleus accumbens and hippocampus. Pharmacology Biochemistry and Behavior, 2008, 89, 384-391.	1.3	37
478	Dysregulation of peripheral endocannabinoid levels in hyperglycemia and obesity: Effect of high fat diets. Molecular and Cellular Endocrinology, 2008, 286, S66-S78.	1.6	145
479	Symptom-related changes of endocannabinoid and palmitoylethanolamide levels in brain areas of R6/2 mice, a transgenic model of Huntington's disease. Neurochemistry International, 2008, 52, 307-313.	1.9	80
480	Regulation of hypothalamic endocannabinoid levels by neuropeptides and hormones involved in food intake and metabolism: Insulin and melanocortins. Neuropharmacology, 2008, 54, 206-212.	2.0	44
481	Functional lipidomics. Calcium-independent activation of endocannabinoid/endovanilloid lipid signalling in sensory neurons by protein kinases C and A and thrombin. Neuropharmacology, 2008, 55, 1274-1279.	2.0	44
482	The analgesic effect of N-arachidonoyl-serotonin, a FAAH inhibitor and TRPV1 receptor antagonist, associated with changes in rostral ventromedial medulla and locus coeruleus cell activity in rats. Neuropharmacology, 2008, 55, 1105-1113.	2.0	46
483	Immunohistochemical localization of anabolic and catabolic enzymes for anandamide and other putative endovanilloids in the hippocampus and cerebellar cortex of the mouse brain. Neuroscience, 2008, 151, 955-968.	1.1	102
484	The anandamide membrane transporter inhibitor, VDM-11, modulates sleep and c-Fos expression in the rat brain. Neuroscience, 2008, 157, 1-11.	1.1	40
485	FAAH and anandamide: is 2-AG really the odd one out?. Trends in Pharmacological Sciences, 2008, 29, 229-233.	4.0	96
486	Brain TRPV1: a depressing TR(i)P down memory lane?. Trends in Pharmacological Sciences, 2008, 29, 594-600.	4.0	32

#	Article	IF	Citations
487	Synthesis, Cannabinoid Receptor Affinity, and Molecular Modeling Studies of Substituted 1-Aryl-5-(1H-pyrrol-1-yl)-1H-pyrazole-3-carboxamides. Journal of Medicinal Chemistry, 2008, 51, 1560-1576.	2.9	65
488	Effect of polyunsaturated fatty acids on endocannabinoid and N-acyl-ethanolamine levels in mouse adipocytes. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2008, 1781, 52-60.	1.2	93
489	The role of the CB1 cannabinoid receptor and its endogenous ligands, anandamide and 2-arachidonoylglycerol, in amphetamine-induced behavioural sensitization. Behavioural Brain Research, 2008, 187, 289-296.	1.2	48
490	CB1 receptor antagonism: biological basis for metabolic effects. Drug Discovery Today, 2008, 13, 1026-1041.	3.2	84
491	Tetrahydrolipstatin Analogues as Modulators of Endocannabinoid 2-Arachidonoylglycerol Metabolism. Journal of Medicinal Chemistry, 2008, 51, 6970-6979.	2.9	76
492	New Analgesics Synthetically Derived from the Paracetamol Metabolite N-(4-Hydroxyphenyl)-(5Z,8Z,11Z,14Z)-icosatetra-5,8,11,14-enamide. Journal of Medicinal Chemistry, 2008, 51, 7800-7805.	2.9	13
493	Investigations on the 4-Quinolone-3-carboxylic Acid Motif. 2. Synthesis and Structureâ^'Activity Relationship of Potent and Selective Cannabinoid-2 Receptor Agonists Endowed with Analgesic Activity in Vivo. Journal of Medicinal Chemistry, 2008, 51, 5075-5084.	2.9	70
494	Play an ADAGIO with a STRADIVARIUS: the right patient for CB1 receptor antagonists?. Nature Clinical Practice Cardiovascular Medicine, 2008, 5, 610-612.	3.3	13
495	Plant-Derived Cannabinoids Modulate the Activity of Transient Receptor Potential Channels of Ankyrin Type-1 and Melastatin Type-8. Journal of Pharmacology and Experimental Therapeutics, 2008, 325, 1007-1015.	1.3	283
496	The cannabinoid CB1 receptor regulates bone formation by modulating adrenergic signaling. FASEB Journal, 2008, 22, 285-294.	0.2	178
497	Editorial [Hot Topic: New Potential Therapies from Vanilloid Transient Receptor Cation (TRPV) Channels (Executive Editors: V. Di Marzo and K. Starowicz)]. Current Pharmaceutical Design, 2008, 14, 1-1.	0.9	2
498	TRPV1 Receptors in the Central Nervous System: Potential for Previously Unforeseen Therapeutic Applications. Current Pharmaceutical Design, 2008, 14, 42-54.	0.9	145
499	Endocannabinoid signaling controls pyramidal cell specification and long-range axon patterning. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 8760-8765.	3.3	263
500	The Endocannabinoid 2-Arachidonoylglycerol Is Responsible for the Slow Self-Inhibition in Neocortical Interneurons. Journal of Neuroscience, 2008, 28, 13532-13541.	1.7	74
501	Role in Anxiety Behavior of the Endocannabinoid System in the Prefrontal Cortex. Cerebral Cortex, 2008, 18, 1292-1301.	1.6	252
502	The Role of the Endocannabinoid System in Alzheimers Disease: Facts and Hypotheses. Current Pharmaceutical Design, 2008, 14, 2299-2305.	0.9	67
503	Endocannabinoids in Energy Homeostasis and Metabolic Disorders. , 2008, , 277-316.		1
504	Attenuation of Allergic Contact Dermatitis Through the Endocannabinoid System. Science, 2007, 316, 1494-1497.	6.0	302

#	Article	IF	Citations
505	Opposing Control of Cannabinoid Receptor Stimulation on Amyloid-Î²-Induced Reactive Gliosis: In Vitro and in Vivo Evidence. Journal of Pharmacology and Experimental Therapeutics, 2007, 322, 1144-1152.	1.3	72
506	Tonic Endovanilloid Facilitation of Glutamate Release in Brainstem Descending Antinociceptive Pathways. Journal of Neuroscience, 2007, 27, 13739-13749.	1.7	152
507	Structure-Based Virtual Screening: Identification of Novel CB2 Receptor Ligands. Letters in Drug Design and Discovery, 2007, 4, 15-19.	0.4	3
508	Endocannabinoids and the regulation of their levels in health and disease. Current Opinion in Lipidology, 2007, 18, 129-140.	1.2	257
509	Endocannabinoids and the control of energy balance. Trends in Endocrinology and Metabolism, 2007, 18, 27-37.	3.1	328
510	Changes in spinal and supraspinal endocannabinoid levels in neuropathic rats. Neuropharmacology, 2007, 52, 415-422.	2.0	209
511	N-Arachidonoyl-Dopamine Tunes Synaptic Transmission onto Dopaminergic Neurons by Activating both Cannabinoid and Vanilloid Receptors. Neuropsychopharmacology, 2007, 32, 298-308.	2.8	141
512	Short- and long-term plasticity of the endocannabinoid system in neuropsychiatric and neurological disorders. Pharmacological Research, 2007, 56, 428-442.	3.1	53
513	New N-Arachidonoylserotonin Analogues with Potential â€œDualâ€•Mechanism of Action against Pain. Journal of Medicinal Chemistry, 2007, 50, 6554-6569.	2.9	58
514	Periaqueductal Gray Metabotropic Glutamate Receptor Subtype 7 and 8 Mediate Opposite Effects on Amino Acid Release, Rostral Ventromedial Medulla Cell Activities, and Thermal Nociception. Journal of Neurophysiology, 2007, 98, 43-53.	0.9	65
515	The 1,2,3â€Triazole Ring as a Peptidoâ€•and Olefinomimetic Element: Discovery of Click Vanilloids and Cannabinoids. Angewandte Chemie - International Edition, 2007, 46, 9312-9315.	7.2	61
516	Enantioselective synthesis of 1-(R)-hydroxypolygodial and its 9Î± epimer, 1-(R)-hydroxyisotadeonal. Tetrahedron, 2007, 63, 6866-6873.	1.0	6
517	Design, synthesis, binding, and molecular modeling studies of new potent ligands of cannabinoid receptors. Bioorganic and Medicinal Chemistry, 2007, 15, 5406-5416.	1.4	16
518	Metabolically labile cannabinoid esters: A â€˜soft drugâ€™ approach for the development of cannabinoid-based therapeutic drugs. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 4878-4881.	1.0	10
519	New 1,8-naphthyridine and quinoline derivatives as CB2 selective agonists. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 6505-6510.	1.0	64
520	Enantioselective synthesis and vanilloid activity evaluation of 1-Î²-(p-methoxycinnamoyl)polygodial, an antinociceptive compound from Drymis winteri barks. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 6444-6447.	1.0	7
521	Endocannabinoids and Related Compounds: Walking Back and Forth between Plant Natural Products and Animal Physiology. Chemistry and Biology, 2007, 14, 741-756.	6.2	115
522	Circulating endocannabinoid levels, abdominal adiposity and related cardiometabolic risk factors in obese men. International Journal of Obesity, 2007, 31, 692-699.	1.6	339

#	Article	IF	Citations
523	Identification of Endocannabinoids and Related Compounds in Human Fat Cells. Obesity, 2007, 15, 837-845.	1.5	82
524	Analgesic actions of N -arachidonoyl-serotonin, a fatty acid amide hydrolase inhibitor with antagonistic activity at vanilloid TRPV1 receptors. British Journal of Pharmacology, 2007, 150, 766-781.	2.7	178
525	Pharmacological enhancement of the endocannabinoid system in the nucleus accumbens shell stimulates food intake and increases c-Fos expression in the hypothalamus. British Journal of Pharmacology, 2007, 151, 1109-1116.	2.7	138
526	Role and regulation of acylethanolamides in energy balance: focus on adipocytes and Î²â€cells. British Journal of Pharmacology, 2007, 152, 676-690.	2.7	95
527	Arvanil, anandamide and N-arachidonoyl-dopamine (NADA) inhibit emesis through cannabinoid CB1 and vanilloid TRPV1 receptors in the ferret. European Journal of Neuroscience, 2007, 25, 2773-2782.	1.2	111
528	Regulation of transient receptor potential channels of melastatin type 8 (TRPM8): Effect of cAMP, cannabinoid CB1 receptors and endovanilloids. Experimental Cell Research, 2007, 313, 1911-1920.	1.2	140
529	Mechanisms for the coupling of cannabinoid receptors to intracellular calcium mobilization in rat insulinoma Î²-cells. Experimental Cell Research, 2007, 313, 2993-3004.	1.2	72
530	Biochemistry and pharmacology of endovanilloids. , 2007, 114, 13-33.		349
531	Palmitoylethanolamide, endocannabinoids and related cannabimimetic compounds in protection against tissue inflammation and pain: Potential use in companion animals. Veterinary Journal, 2007, 173, 21-30.	0.6	165
532	Overactivity of the intestinal endocannabinoid system in celiac disease and in methotrexate-treated rats. Journal of Molecular Medicine, 2007, 85, 523-530.	1.7	64
533	Cannabinoid CB1 receptor stimulation affords neuroprotection in MPTP-induced neurotoxicity by attenuating S100B up-regulation in vitro. Journal of Molecular Medicine, 2007, 85, 1379-1392.	1.7	41
534	The endocannabinoid system for the development of new drugs for spasticity. Drugs of the Future, 2007, 32, 0341.	0.0	9
535	Regulation, Function, and Dysregulation of Endocannabinoids in Models of Adipose and Î²-Pancreatic Cells and in Obesity and Hyperglycemia. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 3171-3180.	1.8	604
536	Antitumor Activity of Plant Cannabinoids with Emphasis on the Effect of Cannabidiol on Human Breast Carcinoma. Journal of Pharmacology and Experimental Therapeutics, 2006, 318, 1375-1387.	1.3	466
537	Increasing cannabinoid levels by pharmacological and genetic manipulation delays disease progression in SOD1 mice. FASEB Journal, 2006, 20, 1003-1005.	0.2	142
538	Development of the First Potential Covalent Inhibitors of Anandamide Cellular Uptake. Journal of Medicinal Chemistry, 2006, 49, 2320-2332.	2.9	22
539	Plant, Synthetic, and Endogenous Cannabinoids in Medicine. Annual Review of Medicine, 2006, 57, 553-574.	5.0	156
540	Anandamide inhibits adhesion and migration of breast cancer cells. Experimental Cell Research, 2006, 312, 363-373.	1.2	149

#	Article	IF	Citations
541	Endocannabinoids Activate Transient Receptor Potential Vanilloid 1 Receptors to Reduce Hyperdopaminergia-Related Hyperactivity: Therapeutic Implications. Biological Psychiatry, 2006, 59, 508-515.	0.7	130
542	Oxyhomologues of Anandamide and Related Endolipids:Â Chemoselective Synthesis and Biological Activity. Journal of Medicinal Chemistry, 2006, 49, 2333-2338.	2.9	20
543	First â€œhybridâ€•ligands of vanilloid TRPV1 and cannabinoid CB2receptors and non-polyunsaturated fatty acid-derived CB2-selective ligands. FEBS Letters, 2006, 580, 568-574.	1.3	26
544	Development of the first potent and specific inhibitors of endocannabinoid biosynthesis. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2006, 1761, 205-212.	1.2	118
545	Evolutionary origins of the endocannabinoid system. Gene, 2006, 370, 64-74.	1.0	153
546	Endocannabinoids: synthesis and degradation. Reviews of Physiology, Biochemistry and Pharmacology, 2006, 160, 1-24.	0.9	221
547	Changes in endocannabinoid and palmitoylethanolamide levels in eye tissues of patients with diabetic retinopathy and age-related macular degeneration. Prostaglandins Leukotrienes and Essential Fatty Acids, 2006, 75, 413-418.	1.0	74
548	A role for vanilloid receptor 1 (TRPV1) and endocannabinnoid signalling in the regulation of spontaneous and L-DOPA induced locomotion in normal and reserpine-treated rats. Neuropharmacology, 2006, 51, 557-565.	2.0	74
549	Immunohistochemical localization of cannabinoid type 1 and vanilloid transient receptor potential vanilloid type 1 receptors in the mouse brain. Neuroscience, 2006, 139, 1405-1415.	1.1	434
550	A brief history of cannabinoid and endocannabinoid pharmacology as inspired by the work of British scientists. Trends in Pharmacological Sciences, 2006, 27, 134-140.	4.0	101
551	Synthesis, conformational analysis and CB1 binding affinity of hairpin-like anandamide pseudopeptide mimetics. Journal of Peptide Science, 2006, 12, 575-591.	0.8	6
552	Neuropathic pain and the endocannabinoid system in the dorsal raphe: pharmacological treatment and interactions with the serotonergic system. European Journal of Neuroscience, 2006, 24, 2011-2020.	1.2	78
553	New potent and selective inhibitors of anandamide reuptake with antispastic activity in a mouse model of multiple sclerosis. British Journal of Pharmacology, 2006, 147, 83-91.	2.7	60
554	In vitro and in vivo pharmacology of synthetic olivetol- or resorcinol-derived cannabinoid receptor ligands. British Journal of Pharmacology, 2006, 149, 431-440.	2.7	16
555	Depolarization-induced retrograde synaptic inhibition in the mouse cerebellar cortex is mediated by 2-arachidonoylglycerol. Journal of Physiology, 2006, 577, 263-280.	1.3	133
556	Endocannabinoids and Î²-amyloid-induced neurotoxicity in vivo: effect of pharmacological elevation of endocannabinoid levels. Cellular and Molecular Life Sciences, 2006, 63, 1410-1424.	2.4	191
557	New metabolically stable fatty acid amide ligands of cannabinoid receptors: Synthesis and receptor affinity studies. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 138-141.	1.0	10
558	Arvanil inhibits T lymphocyte activation and ameliorates autoimmune encephalomyelitis. Journal of Neuroimmunology, 2006, 171, 110-119.	1.1	36

#	Article	IF	Citations
559	Protective activation of the endocannabinoid system during ischemia in dopamine neurons. Neurobiology of Disease, 2006, 24, 15-27.	2.1	89
560	The endocannabinoid and endovanilloid systems and their interactions in neuropathic pain. Drug Development Research, 2006, 67, 339-354.	1.4	22
561	Iodinated N-Acylvanillamines: Potential â€œMultiple-Targetâ€•Anti-Inflammatory Agents Acting via the Inhibition of T-Cell Activation and Antagonism at Vanilloid TRPV1 Channels. Molecular Pharmacology, 2006, 69, 1373-1382.	1.0	18
562	Neural contractions in colonic strips from patients with diverticular disease: role of endocannabinoids and substance P. Gut, 2006, 55, 946-953.	6.1	58
563	Endogenous cannabinoids in the brain and peripheral tissues: regulation of their levels and control of food intake. International Journal of Obesity, 2006, 30, S7-S12.	1.6	119
564	Endocannabinoids, feeding and suckling â€“ from our perspective. International Journal of Obesity, 2006, 30, S24-S28.	1.6	25
565	Upâ€regulation of anandamide levels as an endogenous mechanism and a pharmacological strategy to limit colon inflammation. FASEB Journal, 2006, 20, 568-570.	0.2	198
566	Elevation of Endocannabinoid Levels in the Ventrolateral Periaqueductal Grey through Inhibition of Fatty Acid Amide Hydrolase Affects Descending Nociceptive Pathways via Both Cannabinoid Receptor Type 1 and Transient Receptor Potential Vanilloid Type-1 Receptors. Journal of Pharmacology and Experimental Therapeutics, 2006, 316, 969-982.	1.3	260
567	Cannabinoid CB1 Receptor Mediates Fear Extinction via Habituation-Like Processes. Journal of Neuroscience, 2006, 26, 6677-6686.	1.7	204
568	Endocannabinoid system and its role in energy regulation. Expert Review of Endocrinology and Metabolism, 2006, 1, 557-569.	1.2	4
569	Endocannabinoid overactivity and intestinal inflammation. Gut, 2006, 55, 1373-1376.	6.1	92
570	Forebrain-Specific Inactivation of G q /G 11 Family G Proteins Results in Age-Dependent Epilepsy and Impaired Endocannabinoid Formation. Molecular and Cellular Biology, 2006, 26, 5888-5894.	1.1	73
571	Pharmacological modulation of the endocannabinoid system in a viral model of multiple sclerosis. Journal of Neurochemistry, 2005, 92, 1327-1339.	2.1	131
572	Occurrence and possible biological role of the endocannabinoid system in the sea squirt Ciona intestinalis. Journal of Neurochemistry, 2005, 93, 1141-1156.	2.1	48
573	The endocannabinoid system in the brain of Carassius auratus and its possible role in the control of food intake. Journal of Neurochemistry, 2005, 95, 662-672.	2.1	74
574	Endocannabinoid control of food intake and energy balance. Nature Neuroscience, 2005, 8, 585-589.	7.1	663
575	Anandamide acts as an intracellular messenger amplifying Ca2+ influx via TRPV1 channels. EMBO Journal, 2005, 24, 3026-3037.	3.5	210
576	Anandamide acts as an intracellular messenger amplifying Ca2+ influx via TRPV1 channels. EMBO Journal, 2005, 24, 3517-3518.	3.5	18

#	Article	IF	Citations
577	Effect of repeated systemic administration of selective inhibitors of endocannabinoid inactivation on rat brain endocannabinoid levels. Biochemical Pharmacology, 2005, 70, 446-452.	2.0	81
578	Arvanil, a hybrid endocannabinoid and vanilloid compound, behaves as an antihyperkinetic agent in a rat model of Huntington's disease. Brain Research, 2005, 1050, 210-216.	1.1	37
579	Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis. Neurobiology of Disease, 2005, 20, 207-217.	2.1	131
580	The endocannabinoid signalling system: Biochemical aspects. Pharmacology Biochemistry and Behavior, 2005, 81, 224-238.	1.3	185
581	Anandamide as an intracellular messenger regulating ion channel activity. Prostaglandins and Other Lipid Mediators, 2005, 77, 111-122.	1.0	87
582	Up-regulation of the endocannabinoid system in the uterus of leptin knockout (ob/ob) mice and implications for fertility. Molecular Human Reproduction, 2005, 11, 21-28.	1.3	65
583	Development of the First Ultra-Potent â€œCapsaicinoidâ€•Agonist at Transient Receptor Potential Vanilloid Type 1 (TRPV1) Channels and Its Therapeutic Potential. Journal of Pharmacology and Experimental Therapeutics, 2005, 312, 561-570.	1.3	68
584	Activation of the endocannabinoid system as a therapeutic approach in a murine model of multiple sclerosis. FASEB Journal, 2005, 19, 1338-1340.	0.2	120
585	A role for endocannabinoids in the generation of parkinsonism and levodopaâ€•induced dyskinesia in MPTPâ€•lesioned nonâ€•human primate models of Parkinson's disease. FASEB Journal, 2005, 19, 1140-1142.	0.2	189
586	Blood Levels of the Endocannabinoid Anandamide are Increased in Anorexia Nervosa and in Binge-Eating Disorder, but not in Bulimia Nervosa. Neuropsychopharmacology, 2005, 30, 1216-1221.	2.8	245
587	Identification and Functional Characterization of Brainstem Cannabinoid CB2 Receptors. Science, 2005, 310, 329-332.	6.0	1,357
588	Design, Synthesis, and Binding Studies of New Potent Ligands of Cannabinoid Receptors. Journal of Medicinal Chemistry, 2005, 48, 7343-7350.	2.9	42
589	Targeted lipidomics: endocannabinoids and other endolipid modulators. Life Sciences, 2005, 77, 1517-1518.	2.0	1
590	Lipids as regulators of the activity of transient receptor potential type V1 (TRPV1) channels. Life Sciences, 2005, 77, 1651-1666.	2.0	96
591	Finding of endocannabinoids in human eye tissues: Implications for glaucoma. Biochemical and Biophysical Research Communications, 2005, 330, 1062-1067.	1.0	95
592	Involvement of the cannabimimetic compound, N-palmitoyl-ethanolamine, in inflammatory and neuropathic conditions: Review of the available pre-clinical data, and first human studies. Neuropharmacology, 2005, 48, 1154-1163.	2.0	131
593	Cisplatin increases brain 2-arachidonoylglycerol (2-AG) and concomitantly reduces intestinal 2-AG and anandamide levels in the least shrew. Neuropharmacology, 2005, 49, 502-513.	2.0	42
594	Fatty Acid Amide Hydrolase Controls Mouse Intestinal Motility In Vivo. Gastroenterology, 2005, 129, 941-951.	0.6	114

#	Article	IF	Citations
595	The Biosynthesis, Fate and Pharmacological Properties of Endocannabinoids. Handbook of Experimental Pharmacology, 2005, , 147-185.	0.9	111
596	The Taming of Capsaicin. Reversal of the Vanilloid Activity ofN-Acylvanillamines by Aromatic Iodination. Journal of Medicinal Chemistry, 2005, 48, 4663-4669.	2.9	60
597	Prefrontal Cortex Stimulation Induces 2-Arachidonoyl-Glycerol-Mediated Suppression of Excitation in Dopamine Neurons. Journal of Neuroscience, 2004, 24, 10707-10715.	1.7	232
598	Endocannabinoids Link Feeding State and Auditory Perception-Related Gene Expression. Journal of Neuroscience, 2004, 24, 10013-10021.	1.7	55
599	Prostaglandin Ethanolamides (Prostamides): In Vitro Pharmacology and Metabolism. Journal of Pharmacology and Experimental Therapeutics, 2004, 309, 745-757.	1.3	130
600	A new strategy to block tumor growth by inhibiting endocannabinoid inactivation. FASEB Journal, 2004, 18, 1606-1608.	0.2	140
601	Endovanilloids. Putative endogenous ligands of transient receptor potential vanilloid 1 channels. FEBS Journal, 2004, 271, 1827-1834.	0.2	342
602	Changes in endocannabinoid levels in a rat model of behavioural sensitization to morphine. European Journal of Neuroscience, 2004, 20, 1849-1857.	1.2	86
603	The endocannabinoid system and its therapeutic exploitation. Nature Reviews Drug Discovery, 2004, 3, 771-784.	21.5	879
604	The endocannabinoid system: a general view and latest additions. British Journal of Pharmacology, 2004, 141, 765-774.	2.7	400
605	Actions of two naturally occurring saturated N -acyldopamines on transient receptor potential vanilloid 1 (TRPV1) channels. British Journal of Pharmacology, 2004, 143, 251-256.	2.7	95
606	Changes in endocannabinoid contents in reward-related brain regions of alcohol-exposed rats, and their possible relevance to alcohol relapse. British Journal of Pharmacology, 2004, 143, 455-464.	2.7	73
607	In vivo pharmacological actions of two novel inhibitors of anandamide cellular uptake. European Journal of Pharmacology, 2004, 484, 249-257.	1.7	92
608	Selective inhibition of anandamide cellular uptake versus enzymatic hydrolysisâ€"a difficult issue to handle. European Journal of Pharmacology, 2004, 492, 1-11.	1.7	86
609	Differential diurnal variations of anandamide and 2-arachidonoyl-glycerol levels in rat brain. Cellular and Molecular Life Sciences, 2004, 61, 945-950.	2.4	127
610	The anandamide membrane transporter. Structureâ€"activity relationships of anandamide and oleoylethanolamine analogs with phenyl rings in the polar head group region. Bioorganic and Medicinal Chemistry, 2004, 12, 5161-5169.	1.4	21
611	Behavioral and molecular changes elicited by acute administration of SR141716 to Î”9-tetrahydrocannabinol-tolerant rats: an experimental model of cannabinoid abstinence. Drug and Alcohol Dependence, 2004, 74, 159-170.	1.6	62
612	A structureâ€"activity relationship study on N-arachidonoyl-amino acids as possible endogenous inhibitors of fatty acid amide hydrolase. Biochemical and Biophysical Research Communications, 2004, 314, 192-196.	1.0	63

#	Article	IF	Citations
613	Lipopolysaccharide-induced pulmonary inflammation is not accompanied by a release of anandamide into the lavage fluid or a down-regulation of the activity of fatty acid amide hydrolase. Life Sciences, 2004, 76, 461-472.	2.0	3
614	Further evidence for the existence of a specific process for the membrane transport of anandamide. Biochemical Journal, 2004, 380, 265-272.	1.7	129
615	Effect of maternal under-nutrition on pup body weight and hypothalamic endocannabinoid levels. Cellular and Molecular Life Sciences, 2003, 60, 382-389.	2.4	37
616	Dual effect of cannabinoid CB 1 receptor stimulation on a vanilloid VR1 receptor-mediated response. Cellular and Molecular Life Sciences, 2003, 60, 607-616.	2.4	131
617	The endocannabinoid system in the basal ganglia and in the mesolimbic reward system: implications for neurological and psychiatric disorders. European Journal of Pharmacology, 2003, 480, 133-150.	1.7	249
618	Novel selective and metabolically stable inhibitors of anandamide cellular uptake. Biochemical Pharmacology, 2003, 65, 1473-1481.	2.0	149
619	Capsaicin-like effects of N-arachidonoyl-dopamine in the isolated guinea pig bronchi and urinary bladder. European Journal of Pharmacology, 2003, 475, 107-114.	1.7	35
620	Compounds acting at the endocannabinoid and/or endovanilloid systems reduce hyperkinesia in a rat model of Huntington's disease. Journal of Neurochemistry, 2003, 84, 1097-1109.	2.1	133
621	Manipulation of the endocannabinoid system by a general anaesthetic. British Journal of Pharmacology, 2003, 139, 885-886.	2.7	7
622	Halogenation of a capsaicin analogue leads to novel vanilloid TRPV1 receptor antagonists. British Journal of Pharmacology, 2003, 139, 1417-1424.	2.7	63
623	The CB1/VR1 agonist arvanil induces apoptosis through an FADD/caspase-8-dependent pathway. British Journal of Pharmacology, 2003, 140, 1035-1044.	2.7	26
624	Corrigendum to Halogenation of a capsaicin analogue leads to novel vanilloid TRPVI receptor antagonists. British Journal of Pharmacology, 2003, 140, 1008-1008.	2.7	0
625	Homologues and isomers of noladin ether, a putative novel endocannabinoid: interaction with rat cannabinoid CB1 receptors. Bioorganic and Medicinal Chemistry Letters, 2003, 13, 43-46.	1.0	11
626	Possible endocannabinoid control of colorectal cancer growth. Gastroenterology, 2003, 125, 677-687.	0.6	252
627	An endogenous cannabinoid tone attenuates cholera toxin-induced fluid accumulation in mice. Gastroenterology, 2003, 125, 765-774.	0.6	128
628	Semiplenamides Aâ^'G, Fatty Acid Amides from a Papua New Guinea Collection of the Marine CyanobacteriumLyngbyasemiplena. Journal of Natural Products, 2003, 66, 1364-1368.	1.5	52
629	Endocannabinoids and related fatty acid amides, and their regulation, in the salivary glands of the lone star tick. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2003, 1633, 61-67.	1.2	36
630	CB1 Cannabinoid Receptors and On-Demand Defense Against Excitotoxicity. Science, 2003, 302, 84-88.	6.0	1,083

#	Article	IF	Citations
631	Endocannabinoid signalling in the blood of patients with schizophrenia. Lipids in Health and Disease, 2003, 2, 5.	1.2	228
632	Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain. Journal of Cell Biology, 2003, 163, 463-468.	2.3	923
633	Anandamide Inhibits Nuclear Factor-Î²B Activation through a Cannabinoid Receptor-Independent Pathway. Molecular Pharmacology, 2003, 63, 429-438.	1.0	116
634	N-Oleoyldopamine, a Novel Endogenous Capsaicin-like Lipid That Produces Hyperalgesia. Journal of Biological Chemistry, 2003, 278, 13633-13639.	1.6	303
635	Inhibitory effects of cannabinoid CB 1 receptor stimulation on tumor growth and metastatic spreading: actions on signals involved in angiogenesis and metastasis. FASEB Journal, 2003, 17, 1771-1773.	0.2	173
636	Presynaptic Facilitation of Glutamatergic Synapses to Dopaminergic Neurons of the Rat Substantia Nigra by Endogenous Stimulation of Vanilloid Receptors. Journal of Neuroscience, 2003, 23, 3136-3144.	1.7	237
637	The Endocannabinoid System Protects Rat Glioma Cells Against HIV-1 Tat Protein-induced Cytotoxicity. Journal of Biological Chemistry, 2002, 277, 50348-50354.	1.6	55
638	A Structure/Activity Relationship Study on Arvanil, an Endocannabinoid and Vanilloid Hybrid. Journal of Pharmacology and Experimental Therapeutics, 2002, 300, 984-991.	1.3	83
639	An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 8400-8405.	3.3	874
640	The endocannabinoid system and the molecular basis of paralytic ileus in mice. FASEB Journal, 2002, 16, 1973-1975.	0.2	91
641	N-Acylvanillamides:â€‰ Development of an Expeditious Synthesis and Discovery of New Acyl Templates for Powerful Activation of the Vanilloid Receptor. Journal of Medicinal Chemistry, 2002, 45, 3739-3745.	2.9	57
642	Endocannabinoids as physiological regulators of colonic propulsion in mice. Gastroenterology, 2002, 123, 227-234.	0.6	167
643	Fatty Acid Amide Hydrolase, an Enzyme with Many Bioactive Substrates. Possible Therapeutic Implications. Current Pharmaceutical Design, 2002, 8, 533-547.	0.9	111
644	Noladin ether, a putative novel endocannabinoid: inactivation mechanisms and a sensitive method for its quantification in rat tissues. FEBS Letters, 2002, 513, 294-298.	1.3	104
645	The hypothalamic levels of the endocannabinoid, anandamide, peak immediately before the onset of puberty in female rats. Life Sciences, 2002, 70, 1407-1414.	2.0	56
646	Endocannabinoids in the new millennium. Prostaglandins Leukotrienes and Essential Fatty Acids, 2002, 66, 91-92.	1.0	6
647	Anandamide receptors. Prostaglandins Leukotrienes and Essential Fatty Acids, 2002, 66, 377-391.	1.0	237
648	Arvanil-induced inhibition of spasticity and persistent pain: evidence for therapeutic sites of action different from the vanilloid VR1 receptor and cannabinoid CB1/CB2 receptors. European Journal of Pharmacology, 2002, 439, 83-92.	1.7	80

#	Article	IF	Citations
649	Changes in endocannabinoid contents in the brain of rats chronically exposed to nicotine, ethanol or cocaine. Brain Research, 2002, 954, 73-81.	1.1	253
650	Endovanilloid signaling in pain. Current Opinion in Neurobiology, 2002, 12, 372-379.	2.0	270
651	Enhancement of Anandamide Formation in the Limbic Forebrain and Reduction of Endocannabinoid Contents in the Striatum of Î”9-Tetrahydrocannabinol-Tolerant Rats. Journal of Neurochemistry, 2002, 74, 1627-1635.	2.1	144
652	Effect on cancer cell proliferation of palmitoylethanolamide, a fatty acid amide interacting with both the cannabinoid and vanilloid signalling systems. Fundamental and Clinical Pharmacology, 2002, 16, 297-302.	1.0	85
653	Presence and regulation of the endocannabinoid system in human dendritic cells. FEBS Journal, 2002, 269, 3771-3778.	0.2	157
654	The endogenous cannabinoid system controls extinction of aversive memories. Nature, 2002, 418, 530-534.	13.7	1,603
655	Targeting the endocannabinoid system in cancer therapy: A call for further research. Nature Medicine, 2002, 8, 547-550.	15.2	161
656	Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol. British Journal of Pharmacology, 2002, 136, 550-557.	2.7	674
657	Acute Neuronal Injury, Excitotoxicity, and the Endocannabinoid System. Molecular Neurobiology, 2002, 26, 317-346.	1.9	127
658	Endocannabinoids control spasticity in a multiple sclerosis model. FASEB Journal, 2001, 15, 300-302.	0.2	371
659	Lipopolysaccharide Downregulates Fatty Acid Amide Hydrolase Expression and Increases Anandamide Levels in Human Peripheral Lymphocytes. Archives of Biochemistry and Biophysics, 2001, 393, 321-328.	1.4	152
660	Highly Selective CB1 Cannabinoid Receptor Ligands and Novel CB1/VR1 Vanilloid Receptor â€œHybridâ€• Ligands. Biochemical and Biophysical Research Communications, 2001, 281, 444-451.	1.0	124
661	Anandamide: some like it hot. Trends in Pharmacological Sciences, 2001, 22, 346-349.	4.0	213
662	Evidence for an endocannabinoid system in the central nervous system of the leech Hirudo medicinalis. Molecular Brain Research, 2001, 87, 145-159.	2.5	61
663	Palmitoylethanolamide enhances anandamide stimulation of human vanilloid VR1 receptors. FEBS Letters, 2001, 506, 253-256.	1.3	186
664	Palmitoylethanolamide inhibits the expression of fatty acid amide hydrolase and enhances the anti-proliferative effect of anandamide in human breast cancer cells. Biochemical Journal, 2001, 358, 249.	1.7	124
665	Palmitoylethanolamide inhibits the expression of fatty acid amide hydrolase and enhances the anti-proliferative effect of anandamide in human breast cancer cells. Biochemical Journal, 2001, 358, 249-255.	1.7	174
666	Changes in endocannabinoid transmission in the basal ganglia in a rat model of Huntington's disease. NeuroReport, 2001, 12, 2125-2129.	0.6	91

#	Article	IF	Citations
667	The vanilloid receptor (VR1)-mediated effects of anandamide are potently enhanced by the cAMP-dependent protein kinase. Journal of Neurochemistry, 2001, 77, 1660-1663.	2.1	191
668	Synthesis and biological evaluation of novel amides of polyunsaturated fatty acids with dopamine. Bioorganic and Medicinal Chemistry Letters, 2001, 11, 447-449.	1.0	72
669	Structure-activity relationship for the endogenous cannabinoid, anandamide, and certain of its analogues at vanilloid receptors in transfected cells and vas deferens. British Journal of Pharmacology, 2001, 132, 631-640.	2.7	214
670	Cannabinoid CB1 -receptor mediated regulation of gastrointestinal motility in mice in a model of intestinal inflammation. British Journal of Pharmacology, 2001, 134, 563-570.	2.7	219
671	Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. British Journal of Pharmacology, 2001, 134, 845-852.	2.7	945
672	Inhibitory effect of palmitoylethanolamide on gastrointestinal motility in mice. British Journal of Pharmacology, 2001, 134, 945-950.	2.7	97
673	Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature, 2001, 410, 822-825.	13.7	1,468
674	Critical role of the endogenous cannabinoid system in mouse pup suckling and growth. European Journal of Pharmacology, 2001, 419, 207-214.	1.7	115
675	Hypolocomotor effects in rats of capsaicin and two long chain capsaicin homologues. European Journal of Pharmacology, 2001, 420, 123-131.	1.7	113
676	The Activity of Anandamide at Vanilloid VR1 Receptors Requires Facilitated Transport across the Cell Membrane and Is Limited by Intracellular Metabolism. Journal of Biological Chemistry, 2001, 276, 12856-12863.	1.6	320
677	Endocannabinoids Part II: pathological CNS conditions involving the endocannabinoid system and their possible treatment with endocannabinoid-based drugs. Expert Opinion on Therapeutic Targets, 2001, 5, 349-362.	1.5	4
678	Control by the endogenous cannabinoid system of ras oncogeneâ€dependent tumor growth. FASEB Journal, 2001, 15, 1-17.	0.2	123
679	Anandamide and diet: Inclusion of dietary arachidonate and docosahexaenoate leads to increased brain levels of the corresponding N-acylethanolamines in piglets. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 6402-6406.	3.3	240
680	Evidence for a New G Protein-Coupled Cannabinoid Receptor in Mouse Brain. Molecular Pharmacology, 2001, 60, 155-163.	1.0	523
681	Identification of a New Class of Molecules, the Arachidonyl Amino Acids, and Characterization of One Member That Inhibits Pain. Journal of Biological Chemistry, 2001, 276, 42639-42644.	1.6	297
682	Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Molecular Pharmacology, 2001, 60, 155-63.	1.0	166
683	N-acyl-dopamines: novel synthetic CB1 cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo. Biochemical Journal, 2000, 351, 817.	1.7	113
684	N-acyl-dopamines: novel synthetic CB1 cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo. Biochemical Journal, 2000, 351, 817-824.	1.7	315

#	Article	IF	Citations
685	Comparative biology of the endocannabinoid system. FEBS Journal, 2000, 267, 4917-4927.	0.2	106
686	Endocannabinoids and fatty acid amides in cancer, inflammation and related disorders. Chemistry and Physics of Lipids, 2000, 108, 191-209.	1.5	154
687	Anandamide and other cannabimimetic fatty acid derivativesâ€"foreword. Prostaglandins and Other Lipid Mediators, 2000, 61, 1-2.	1.0	0
688	Cannabimimetic fatty acid derivatives in cancer and inflammation. Prostaglandins and Other Lipid Mediators, 2000, 61, 43-61.	1.0	58
689	Role of the endogenous cannabinoid system in the formalin test of persistent pain in the rat. European Journal of Pharmacology, 2000, 396, 85-92.	1.7	90
690	Neurobehavioral activity in mice of N-vanillyl-arachidonyl-amide. European Journal of Pharmacology, 2000, 406, 363-374.	1.7	75
691	Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease. FASEB Journal, 2000, 14, 1432-1438.	0.2	292
692	Suppression of Nerve Growth Factor Trk Receptors and Prolactin Receptors by Endocannabinoids Leads to Inhibition of Human Breast and Prostate Cancer Cell Proliferation1. Endocrinology, 2000, 141, 118-126.	1.4	245
693	Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease. FASEB Journal, 2000, 14, 1432-1438.	0.2	227
694	Anandamide Uptake by Human Endothelial Cells and Its Regulation by Nitric Oxide. Journal of Biological Chemistry, 2000, 275, 13484-13492.	1.6	175
695	Sex Steroid Influence on Cannabinoid CB1 Receptor mRNA and Endocannabinoid Levels in the Anterior Pituitary Gland. Biochemical and Biophysical Research Communications, 2000, 270, 260-266.	1.0	172
696	Endocannabinoids and multiple sclerosis: a blessing from the â€˜inner blissâ€™?. Trends in Pharmacological Sciences, 2000, 21, 195-197.	4.0	15
697	Anandamide â€“ the other side of the coin. Trends in Pharmacological Sciences, 2000, 21, 43-44.	4.0	66
698	New perspectives on enigmatic vanilloid receptors. Trends in Neurosciences, 2000, 23, 491-497.	4.2	207
699	Overlap between the ligand recognition properties of the anandamide transporter and the VR1 vanilloid receptor: inhibitors of anandamide uptake with negligible capsaicin-like activity. FEBS Letters, 2000, 483, 52-56.	1.3	320
700	N-acyl-dopamines: novel synthetic CB(1) cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo. Biochemical Journal, 2000, 351 Pt 3, 817-24.	1.7	99
701	Cannabinoid properties of methylfluorophosphonate analogs. Journal of Pharmacology and Experimental Therapeutics, 2000, 294, 1209-18.	1.3	33
702	Biosynthesis and inactivation of the endocannabinoid 2-arachidonoylglycerol in circulating and tumoral macrophages. FEBS Journal, 1999, 264, 258-267.	0.2	264

#	Article	IF	Citations
703	Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature, 1999, 400, 452-457.	13.7	2,022
704	Metabolism of anandamide and 2-arachidonoylglycerol: An historical overview and some recent developments. Lipids, 1999, 34, S319-S325.	0.7	73
705	Analysis of cannabinoid receptor binding and mRNA expression and endogenous cannabinoid contents in the developing rat brain during late gestation and early postnatal period. , 1999, 33, 181-191.		247
706	Finding of the endocannabinoid signalling system in Hydra, a very primitive organism: possible role in the feeding response. Neuroscience, 1999, 92, 377-387.	1.1	150
707	Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action, by V. Di Marzo, D. Melck, T. Bisogno and L. De Petrocellis, Vol. 21, pp. 521â€“528.. Trends in Neurosciences, 1999, 22, 80.	4.2	4
708	Biosynthesis and inactivation of endocannabinoids: Relevance to their proposed role as neuromodulators. Life Sciences, 1999, 65, 645-655.	2.0	74
709	Involvement of the cAMP/protein kinase A pathway and of mitogen-activated protein kinase in the anti-proliferative effects of anandamide in human breast cancer cells. FEBS Letters, 1999, 463, 235-240.	1.3	145
710	Biosynthesis and Inactivation of N-Arachidonoylethanolamine (Anandamide) and N-Docosahexaenoylethanolamine in Bovine Retina. Archives of Biochemistry and Biophysics, 1999, 370, 300-307.	1.4	117
711	Brain Regional Distribution of Endocannabinoids: Implications for Their Biosynthesis and Biological Function. Biochemical and Biophysical Research Communications, 1999, 256, 377-380.	1.0	288
712	Unsaturated Long-Chain N-Acyl-vanillyl-amides (N-AVAMs): Vanilloid Receptor Ligands That Inhibit Anandamide-Facilitated Transport and Bind to CB1 Cannabinoid Receptors. Biochemical and Biophysical Research Communications, 1999, 262, 275-284.	1.0	183
713	Identification of Endocannabinoids and Cannabinoid CB₁ Receptor mRNA in the Pituitary Gland. Neuroendocrinology, 1999, 70, 137-145.	1.2	78
714	Cannabimimetic fatty acid derivatives: the anandamide family and other endocannabinoids. Current Medicinal Chemistry, 1999, 6, 721-44.	1.2	32
715	The palmitoylethanolamide and oleamide enigmas : are these two fatty acid amides cannabimimetic?. Current Medicinal Chemistry, 1999, 6, 757-73.	1.2	70
716	Cannabimimetic Fatty Acid Derivatives: The Anandamide Family and Other 'Endocannabinoids'. Current Medicinal Chemistry, 1999, 6, 721-744.	1.2	118
717	The Palmitoylethanolamide and Oleamide Enigmas: Are These Two Fatty Acid Amides Cannabimimetic?. Current Medicinal Chemistry, 1999, 6, 757-773.	1.2	218
718	An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity. European Journal of Pharmacology, 1998, 353, 23-31.	1.7	515
719	Endocannabinoids. European Journal of Pharmacology, 1998, 359, 1-18.	1.7	432
720	Biosynthesis and degradation of bioactive fatty acid amides in human breast cancer and rat pheochromocytoma cells. Implications for cell proliferation and differentiation. FEBS Journal, 1998, 254, 634-642.	0.2	91

#	Article	IF	Citations
721	Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action. Trends in Neurosciences, 1998, 21, 521-528.	4.2	635
722	Bioactive long chain N-acylethanolamines in five species of edible bivalve molluscs. Lipids and Lipid Metabolism, 1998, 1389, 101-111.	2.6	55
723	â€˜Endocannabinoidsâ€™ and other fatty acid derivatives with cannabimimetic properties: biochemistry and possible physiopathological relevance. Lipids and Lipid Metabolism, 1998, 1392, 153-175.	2.6	285
724	Interactions between synthetic vanilloids and the endogenous cannabinoid system. FEBS Letters, 1998, 436, 449-454.	1.3	143
725	Arachidonoylserotonin and Other Novel Inhibitors of Fatty Acid Amide Hydrolase. Biochemical and Biophysical Research Communications, 1998, 248, 515-522.	1.0	172
726	Biochemistry of the Endogenous Ligands of Cannabinoid Receptors. Neurobiology of Disease, 1998, 5, 386-404.	2.1	113
727	v-K-ras leads to preferential farnesylation of p21ras in FRTL-5 cells: Multiple interference with the isoprenoid pathway. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 13646-13651.	3.3	21
728	The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 8375-8380.	3.3	364
729	The novel endogenous cannabinoid 2-arachidonoylglycerol is inactivated by neuronal- and basophil-like cells: connections with anandamide. Biochemical Journal, 1998, 331, 15-19.	1.7	195
730	Biosynthesis, Uptake, and Degradation of Anandamide and Palmitoylethanolamide in Leukocytes. Journal of Biological Chemistry, 1997, 272, 3315-3323.	1.6	342
731	The effects of anandamide on memory consolidation in mice involve both D1and D2 dopamine receptors. Behavioural Pharmacology, 1997, 8, 707-712.	0.8	43
732	Biosynthesis, release and degradation of the novel endogenous cannabimimetic metabolite 2-arachidonoylglycerol in mouse neuroblastoma cells. Biochemical Journal, 1997, 322, 671-677.	1.7	254
733	Novel Inhibitors of Brain, Neuronal, and Basophilic Anandamide Amidohydrolase. Biochemical and Biophysical Research Communications, 1997, 231, 82-88.	1.0	112
734	The Sleep Inducing Factor Oleamide Is Produced by Mouse Neuroblastoma Cells. Biochemical and Biophysical Research Communications, 1997, 239, 473-479.	1.0	63
735	Occurrence and metabolism of anandamide and related acyl-ethanolamides in ovaries of the sea urchin Paracentrotus lividus. Lipids and Lipid Metabolism, 1997, 1345, 338-348.	2.6	76
736	Arachidonic acid as an endogenous signal for the glutathione-induced feeding response in Hydra. Cellular and Molecular Life Sciences, 1997, 53, 61-68.	2.4	9
737	Biosynthesis of 2-Arachidonoyl-Glycerol, a Novel Cannabimimetic Eicosanoid, in Mouse Neuroblastoma Cells. Advances in Experimental Medicine and Biology, 1997, 433, 201-204.	0.8	17
738	Potential Biosynthetic Connections between the Two Cannabimimetic Eicosanoids, Anandamide and 2-Arachidonoyl-Glycerol, in Mouse Neuroblastoma Cells. Biochemical and Biophysical Research Communications, 1996, 227, 281-288.	1.0	87

#	Article	IF	Citations
739	Biosynthesis of anandamide and related acylethanolamides in mouse J774 macrophages and N18 neuroblastoma cells. Biochemical Journal, 1996, 316, 977-984.	1.7	198
740	Ï‰10-Lipoxygenase products of Î±-linolenic acid are esterified to phospholipids inHydra vulgaris. Experientia, 1996, 52, 120-126.	1.2	3
741	Hydra vulgaris Ï‰10-lipoxygenase is used in vivo to synthesize new Î±-linolenic acid metabolites. Experientia, 1995, 51, 48-56.	1.2	4
742	Anandamide, an endogenous cannabinomimetic eicosanoid: â€˜Killing two birds with one stoneâ€™. Prostaglandins Leukotrienes and Essential Fatty Acids, 1995, 53, 1-11.	1.0	145
743	Arachidonic acid and eicosanoids as targets and effectors in second messenger interactions. Prostaglandins Leukotrienes and Essential Fatty Acids, 1995, 53, 239-254.	1.0	89
744	Analysis of anandamide, an endogenous cannabinoid substance, and of other natural N-acylethanolamines. Prostaglandins Leukotrienes and Essential Fatty Acids, 1995, 53, 301-308.	1.0	71
745	Phospholipase A2 and protein kinase C enzymatic activities and their interactions in Hydra vulgaris. Comparative Biochemistry and Physiology - B Biochemistry and Molecular Biology, 1995, 111, 211-219.	0.7	5
746	Two novel classes of neuroactive fatty acid amides are substrates for mouse neuroblastoma â€˜anandamide amidohydrolaseâ€™. FEBS Letters, 1995, 377, 82-86.	1.3	184
747	Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature, 1994, 372, 686-691.	13.7	1,462
748	Aquatic invertebrates open up new perspectives in eicosanoid research: Biosynthesis and bioactivity. Prostaglandins Leukotrienes and Essential Fatty Acids, 1994, 51, 215-229.	1.0	49
749	Enantiospecific synthesis of bioactive hydroxyeicosatetraenoic acids (HETEs) in Hydra magnipapillata. Lipids and Lipid Metabolism, 1994, 1213, 215-223.	2.6	14
750	Histological and biochemical bases of defense mechanisms in four species of Polybranchioidea ascoglossan molluscs. Marine Biology, 1993, 117, 367-380.	0.7	28
751	Arachidonic acid, protein kinase C activators and bud formation in Hydra vulgaris. Comparative Biochemistry and Physiology Part C: Comparative Pharmacology, 1993, 105, 219-224.	0.2	5
752	Biosynthesis of hydroxyeicosatetraenoic acids (HETEs) in marine and freshwater hydroids. Comparative Biochemistry and Physiology Part B: Comparative Biochemistry, 1993, 106, 901-906.	0.2	2
753	The effect of a cAMP analogue on Ca2+ ionophore-, antigen- and agonist-induced inositol phosphate release in rat basophilic leukemia (RBL-1) cells. Biochimica Et Biophysica Acta - Molecular Cell Research, 1992, 1133, 218-222.	1.9	2
754	Î±-and Î³-Pyrone-polyÂ·propionates from the mediterranean ascoglossan mollusc ercolania funerea. Tetrahedron, 1992, 48, 9561-9566.	1.0	34
755	Prostaglandin F-1,15-lactone fatty acyl esters: a prostaglandin lactone pathway branch developed during the reproduction and early larval stages of a marine mollusc. Comparative Biochemistry and Physiology Part B: Comparative Biochemistry, 1992, 101, 99-104.	0.2	11
756	Minireview: Interactions between second messengers: Cyclic AMP and phospholipase A2- and phospholipase C-metabolites. Life Sciences, 1991, 49, 247-259.	2.0	32

#	Article	IF	Citations
757	The effect of diterpenoidic diacylglycerols on tentacle regeneration in Hydra vulgaris. Comparative Biochemistry and Physiology Part C: Comparative Pharmacology, 1991, 100, 603-607.	0.2	8
758	A marine mollusc provides the first example of in vivo storage of prostaglandins: Prostaglandin-1,15-lactones. Experientia, 1991, 47, 56-60.	1.2	27
759	A histological and chemical study of the cerata of the opisthobranch molluscTethys fimbria. Marine Biology, 1991, 111, 353-358.	0.7	17
760	Cyercenes, novel polypropionate pyrones from the autotomizing mediterranean mollusc cyerce cristallina. Tetrahedron, 1991, 47, 5569-5576.	1.0	64
761	Oxytoxins, bioactive molecules produced by the marine opisthobranch molluscOxynoe olivacea from a diet-derived precursor. Experientia, 1990, 46, 767-770.	1.2	55
762	High molecular weight polyacetylenes from Petrosia ficiformis: Further structural analysis and biological activity. Tetrahedron Letters, 1989, 30, 3563-3566.	0.7	40
763	Neuropeptides and inflammatory mediators: bidirectional regulatory mechanisms. Trends in Pharmacological Sciences, 1989, 10, 91-92.	4.0	11
764	Antithrombin Chicago, amino acid substitution of arginine 393 to histidine. Thrombosis Research, 1989, 54, 613-619.	0.8	19
765	The synthesis, release and action of leukotrienes in the isolated, unstimulated, buffer-perfused rat heart. Journal of Molecular and Cellular Cardiology, 1989, 21, 1101-1110.	0.9	11
766	The role of cyclic AMP in the inhibition of leukotriene biosynthesis by neuropeptides. European Journal of Pharmacology, 1989, 162, 115-121.	1.7	8
767	Neuropeptides and leukotriene biosynthesis: The effect of calcitonin, peptide histidine valine-42, helodermin, neuropeptide Y and galanin. Neuropeptides, 1988, 11, 169-172.	0.9	4
768	PAF-mediated leukotriene biosynthesis in lungs : Control by the neuropeptidergic system. Prostaglandins, 1987, 34, 185.	1.2	1
769	Neuropeptides and leukotriene release: Effect of peptide histidine isoleucine and secretin in platelet activating factor-stimulated rat lung. Neuropeptides, 1987, 9, 51-58.	0.9	9
770	Platelet activating factor-mediated leukotriene biosynthesis in rat lungs: effect of prostaglandins E1 and F1a. Biochemical and Biophysical Research Communications, 1987, 147, 1213-1218.	1.0	14
771	Investigation of the structure/activity relationship of human calcitonin gene-related peptide (CGRP). Biochemical and Biophysical Research Communications, 1986, 134, 1306-1311.	1.0	67
772	RIA/chromatographic evidence for novel opioid peptide(s) in ganglia. Neuropeptides, 1986, 7, 281-289.	0.9	3
773	Native opioid-like peptides in Squilla mantis ganglia. Peptides, 1985, 6, 403-406.	1.2	3
774	Î²-Endorphin in Neoroblastoma x Glioma hybrid cells. Neuropeptides, 1985, 6, 53-57.	0.9	4

#	Article	IF	Citations
775	A Designer Diet Induces Thermogenic Adipocytes via Raptor and Prolongs Healthy Lifespan. SSRN Electronic Journal, 0, , .	0.4	0